US20230416374A1 - Selective elimination of erosive cells - Google Patents

Selective elimination of erosive cells Download PDF

Info

Publication number
US20230416374A1
US20230416374A1 US18/321,810 US202318321810A US2023416374A1 US 20230416374 A1 US20230416374 A1 US 20230416374A1 US 202318321810 A US202318321810 A US 202318321810A US 2023416374 A1 US2023416374 A1 US 2023416374A1
Authority
US
United States
Prior art keywords
antibody
nkg2a
cells
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US18/321,810
Inventor
Kalle Soederstroem
Elisabeth Douglas Galsgaard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to US18/321,810 priority Critical patent/US20230416374A1/en
Assigned to NOVO NORDISK A/S reassignment NOVO NORDISK A/S ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SOEDERSTROEM, KALLE, GALSGAARD, Elisabeth Douglas
Publication of US20230416374A1 publication Critical patent/US20230416374A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

  • the present invention relates to treatment of bone erosion and cartilage destruction, in particular treatment of bone and cartilage destroying diseases using biological drugs such as antibodies.
  • NK cells are bone marrow derived lymphocytes essential for host defense against certain infections and tumors. Upon activation they rapidly produce a range of cytokines and can mediate cytotoxic responses against infected, stressed, or tumorigenic cells.
  • the role of NK cells in chronic inflammatory diseases is emerging, and it is becoming increasingly appreciated that NK cells may play an important role in the modulation of T and B cell responses through their capacity to promote differentiation and maturation of dendritic cells (DC) and subsequent polarization of T cell responses (see, e.g., Cooper et al. (2004) Trends Immunol. 25: 47-52; Zhang et al. (2007) Blood Oct 1;110(7):2484-93).
  • DC dendritic cells
  • NK cells have the capacity to directly eliminate subsets of activated T cells via cell-mediated cytotoxic responses (Lu et al. (2007) Immunity. 26: 593-604).
  • NK cell activity is regulated by a complex mechanism that involves both activating and inhibitory signals (see, e.g., Moretta et al. (2001) Annu Rev Immunol 19:197-223; Moretta et al. (2003) EMBO J EPub December 18; Ravetch et al. (2000) Science 290:84-89; Zambello et al. (2003) Blood 102:1797-805; Moretta et al. (1997) Curr Opin Immunol 9:694-701.
  • NK-specific receptors have been identified that are involved in NK cell mediated recognition and killing of HLA Class I deficient target cells.
  • One import inhibitory NK cell receptor is CD94/NKG2A, which interacts with the non-classical MHC class I molecule HLA-E (see, e.g., Braud et al. (1998) Nature 391:795-799; Lee et al. (1998) PNAS 95:5199-5204; Vance et al. (2002) PNAS 99:868-873; Brooks et al. (199) J Immunol 162:305-313; Miller et al. (2003) J Immunol 171:1369-75; Brooks et al. (1997) J Exp Med 185:795-800; Van Beneden et al. (2001) 4302-4311; US Patent application no. 20030095965).
  • CD94/NKG2A is an inhibitory receptor found on subsets of NK, NKT and T cells, which restricts their killing of cells expressing the CD94/NKG2A-ligand HLA-E carrying small peptides typically derived from the leader sequence of other MHC class I molecules (see, e.g., WO99/28748 and Braud et al. (1998) Nature 391:795-799).
  • Rheumatoid arthritis is a chronic inflammatory disease where activation of inflammatory mediators produced by multiple cellular subsets eventually results in destruction of joint cartilage and bone. It is generally accepted that the main cellular subsets responsible for cartilage and bone destruction in RA are fibroblast-like synoviocytes (FLS) and osteoclasts, respectively.
  • FLS fibroblast-like synoviocytes
  • CD94-NKG2A expressing T cells and NK cells can suppress inflammation by killing activated proinflammatory cells. Activation of these cells can be accomplished by a series of different cells and molecules including macrophages, activated CD4+ T cells and B cells/plasma cells.
  • NNC141-0100 enhances anti-inflammatory activities of regulatory CD94-NKG2A+T cells and NK cells, boosting their ability to eliminate e.g. activated pro-inflammatory CD4+ T cells and fibroblast-like synoviocytes (FLS).
  • a therapy that specifically eliminates aggressive cartilage-eroding FLS and suppresses the formation of bone erosive osteoclasts while leaving resting cells unaffected may have a significant advantage over current RA therapies and could potentially also, with benefit for the patients, be used in treating osteoarthritis (OA) and psoriatic arthritis (PsA).
  • OA osteoarthritis
  • PsA psoriatic arthritis
  • This invention discloses how an anti-NKG2A antibody attenuates two major pathogenic pathways in RA, i.e. bone and cartilage erosion, by its capacity to reduce formation of bone-degrading osteoclasts and by selectively enhancing elimination of cartilage-degrading FLS, respectively.
  • Anti-NKG2A mAbs capable of inhibiting binding of HLA-E or which can non-competitively block the function of CD94/NKG2A and stimulate the endogenous immune-regulatory mechanism of NK cells result in selective elimination of cells that promote cartilage degradation, bone erosion and reduction in IL-6, a cytokine known to promote inflammation.
  • therapeutic treatment with an anti-NKG2A mAb can have a direct effect on the pathogenesis in diseases characterized by bone erosion or cartilage destruction.
  • the present invention discloses the use of an anti-NKG2A antibody, or a fragment thereof, capable of treating cartilage destruction and/or bone erosion.
  • the present invention discloses the use of an anti-NKG2A antibody for the treatment of a disease or disorder characterized by cartilage destruction and/or bone erosion.
  • the present invention discloses the use of an anti-NKG2A antibody for the treatment of cartilage destruction and/or bone erosion wherein the anti-NKG2A antibody stimulates selective elimination of activated cells that promote cartilage degradation or bone erosion.
  • the cartilage-degrading cells are fibroblast-like synoviocytes (FLS).
  • the bone-eroding cells are erosive osteoclasts.
  • the present invention discloses the use of an anti-NKG2A antibody for the treatment of a disease or disorder characterized by cartilage destruction and/or bone erosion, wherein the anti-NKG2A antibody stimulates selective elimination of activated cells that promote cartilage degradation or bone erosion.
  • the cartilage-degrading cells are fibroblast-like synoviocytes (FLS).
  • the bone-eroding cells are erosive osteoclasts.
  • the NKG2A antibodies used in the current invention can be any suitable anti-NKG2A antibodies.
  • the antibody is a monoclonal anti-NKG2A antibody.
  • the antibody is a humanized anti-NKG2A antibody.
  • the antibody is a fully human anti-NKG2A antibody.
  • the antibody is an anti-NKG2A antibody as described in WO2008/009545.
  • the anti-NKG2A monoclonal antibody is humZ270 as described in patent publication WO2008/009545.
  • the anti-NKG2A antibody is a monoclonal anti-NKG2A antibody as described in patent publication WO09092805.
  • the anti-NKG2A antibody is humZ199 as described in patent publication WO09092805.
  • FIGS. 1 A .- 1 E illustrate the expression profile of a panel of cell surface molecules expressed by in vitro generated fibroblast-like synoviocytes derived from the synovial tissue of patients with rheumatoid arthritis (RA).
  • RA rheumatoid arthritis
  • FIGS. 2 A .- 2 H. show that NKG2A expressing NK cells are present in RA synovium and can be found in areas containing HLA-E expressing RA-FLS.
  • FIGS. 3 A .- 3 D show that NK cells, including synovial NK cells derived from RA patients, express a panel of activating receptors known to bind to ligands that are expressed on RA-FLS.
  • FIGS. 4 A .- 4 E. show that RA-FLS are protected from NK cell-mediated cytotoxicity by expression of HLA-E capable of ligating to inhibitory CD94-NKG2A NK cell receptors.
  • FIG. 5 A shows that blocking NKG2A using NNC141-0100 (humZ270) leads to increased NK cell-mediated elimination of RA-FLS as measured by an LDH release assay.
  • NKL effector cells are shown on the left and Nishi NK cells on the right against a representative RA-FLS target cell.
  • FIG. 5 B shows that blocking NKG2A using NNC141-0100 (humZ270) leads to increased lysis of a representative RA-FLS (RA-FLS2) but does not affect elimination of a normal foreskin fibroblast cell line (FSK4).
  • NNC141-0100 humZ270
  • FIGS. 6 A .- 6 G. show that NNC141-0100 (humZ270) inhibits formation of TRAP+ multinucleated osteoclasts:
  • FIG. 7 A shows modulation of cytokine levels as measured at 24 hrs in SFMC in vitro cultures upon treatment with humZ270 (NNC141-0100, dark gray bars) as compared to an isotype control (light gray bars).
  • humZ270 NNC141-0100, dark gray bars
  • isotype control light gray bars
  • FIG. 7 C shows that anti-NKG2A inhibits both baseline (i.e. medium alone) and IL-15 stimulated IL-6 production in ex vivo cultures of SFMC derived from patients with RA. Mean and SD of two representative RA patients are shown.
  • FIGS. 8 A .- 8 M show that NK cells present in RA synovial tissue express the inhibitory NKG2A receptor and are localized predominantly in lymphoid aggregates adjacent to synoviocytes that express HLA-E, the ligand for CD94-NKG2A.
  • FIGS. 9 A .- 9 C. show that NKG2A and its ligand, HLA-E, are expressed in synovium of patients with osteoarthritis (OA).
  • FIGS. 10 A .- 10 D. show that the CD94-NKG2A ligand was found to be expressed in inflamed synovium from not only RA and OA patients, but also PsA patients.
  • FIGS. 11 A .- 11 E. show the amino acid sequence of:
  • antibody refers to a polypeptide derived from a germline immunoglobulin sequence.
  • the term includes full-length antibodies and any antigen binding fragments or single chains thereof.
  • the terms “antibody”, “monoclonal antibody” and “mAb”, as used herein, are intended to refer to immunoglobulin molecules and fragments thereof that have the ability to specifically bind to an antigen.
  • a sub-class of the immunoglobulins of particular pharmaceutical interest are those belonging to the IgG family, which can be subdivided into the iso-types IgG1, IgG2, IgG3 and IgG4.
  • IgG molecules are composed of two heavy chains interlinked by two or several disulfide bonds and two light chains, one attached to each of the heavy chains by a disulfide bond.
  • the IgG heavy chain is composed of four Ig-domains, including the variable domain (VH) and three constant domains (CH1, CH2, and CH3).
  • Each light chain is comprised of a light chain variable region (VL) and a light chain constant region (CL).
  • the variable regions of the heavy and light chains contain a binding domain that interacts with an antigen.
  • the VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FR).
  • CDRs complementarity determining regions
  • FR framework regions
  • Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR
  • the constant regions of the antibodies may mediate the binding of the antibody to host tissues or factors, including various cells of the immune system (e.g., effector cells), Fc receptors (FcRs) and the first component (C1q) of the classical complement system. Binding to FcRs and C1q may mediate effects such as ADCC or CDC.
  • various cells of the immune system e.g., effector cells
  • FcRs Fc receptors
  • C1q first component of the classical complement system. Binding to FcRs and C1q may mediate effects such as ADCC or CDC.
  • An antibody of the invention may be any NKG2A binding antibody, the humZ270 antibody (SEQ. ID. NO. 2 and SEQ. ID. NO. 3) or the humZ199 antibody (SEQ. ID. NO. 4 and SEQ. ID. NO. 5) or any other antibody of the invention, or a variant of any one of these antibodies.
  • humanized Z270 or humZ270 or hZ270 comprises the antibody disclosed in the patent application WO08009545, which is hereby incorporated by reference into this application.
  • humanized Z199 or humZ199 as used herein comprises the antibody disclosed in the patent publication WO09092805, which is hereby incorporated by reference into this application.
  • Ab comprises an antibody, or a fragment thereof, which specifically binds its corresponding Ag.
  • antigen-binding fragments include, but are not restricted to, Fab, Fab′, F(ab)2, F(ab′)2, Fv (typically the VL and VH domains of a single arm of an antibody), single-chain Fv (scFv; see, e.g., Bird et al., Science 1988; 242:425-426; and Huston et al.
  • dsFv, Fd typically the VH and CHI domain
  • dAb typically a VH domain
  • VH, VL, VhH, and V-NAR domains monovalent molecules comprising a single VH and a single VL chain
  • minibodies, diabodies, triabodies, tetrabodies, and kappa bodies see, e.g., Ill et al., Protein Eng 1997; 10:949-57
  • antigen-binding fragment of an antibody refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen, such as NKG2A or another target molecule as described herein. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments encompassed within the term “antigen-binding fragment” of an antibody include a Fab fragment, a F(ab′)2 fragment, a Fab′ fragment, a Fd fragment, a Fv fragment, a ScFv fragment, a dAb fragment and an isolated complementarity determining region (CDR).
  • CDR complementarity determining region
  • Single chain antibodies such as scFv and heavy chain antibodies such as VHH and single domain camel antibodies are also intended to be encompassed within the term “antigen-binding portion” of an antibody.
  • antibody fragments may be obtained using conventional techniques known to those of skill in the art, and the fragments may be screened for utility in the same manner as intact antibodies.
  • a “Fab” fragment includes a variable domain and a constant domain of the light chain and a variable domain and the first constant domain (CH1) of the heavy chain.
  • a Fab′ fragment includes one or more cysteine carboxy terminal linkages to the heavy or light chains.
  • F(ab′)2 antibody fragments comprise a pair of Fab fragments that are generally covalently linked near their carboxy termini by hinge cysteines. Other chemical couplings of antibody fragments are also known in the art.
  • a Fab fragment retains the ability of the parent antibody to bind to its antigen, potentially with a lower affinity.
  • F(ab′)2 fragments are capable of divalent binding, whereas Fab fragments can bind monovalently only.
  • Fab fragments lack the constant CH2 and CH3 domains, i.e. the Fc part, where interaction with the Fc receptors would occur.
  • Fab fragments are in general devoid of effector functions.
  • an “Fv” fragment is an antibody fragment that contains a complete antigen recognition and binding site, and generally comprises a dimer of one heavy and one light chain variable domain in tight association that can be covalent in nature, for example in a single chain variable domain fragment (scFv). It is in this configuration that the three hypervariable regions of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer. Collectively, the six hypervariable regions or a subset thereof confer antigen binding specificity to the antibody. However, even a single variable domain comprising only three hypervariable regions specific for an antigen has the ability to recognize and bind the antigen, although usually at a lower affinity than the entire binding site (Cai & Garen, Proc. Natl.
  • VHH heavy chain variable domain
  • Single-chain Fv or “scFv” antibody fragments comprise the VH and VL domains of the antibody, where these domains are present in a single polypeptide chain.
  • the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains that enables the scFv to form the desired structure for antigen binding.
  • diabodies refers to small antibody fragments with two antigen-binding sites, in which fragments comprise a heavy chain variable domain (VH) connected to a light chain variable domain (VL) in the same polypeptide chain (VH and VL).
  • VH heavy chain variable domain
  • VL light chain variable domain
  • VH and VL polypeptide chain
  • linear antibodies refers to antibodies as described in Zapata et al., 1995, Protein Eng., 8(10):1057-1062. Briefly, these antibodies contain a pair of tandem Fd segments (VH-CH1-VH-CH1) that, together with complementary light chain polypeptides, form a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific.
  • the term “monobody”, as used herein, refers to an antigen-binding molecule with a heavy chain variable domain and no light chain variable domain.
  • a monobody can bind to an antigen in the absence of light chains and typically has three hypervariable regions, for example CDRs designated CDRH1, CDRH2, and CDRH3.
  • a heavy chain IgG monobody has two heavy chain antigen-binding molecules connected by a disulfide bond.
  • the heavy chain variable domain comprises one or more hypervariable regions, preferably a CDRH3 or HVL-H3 region.
  • hypervariable region refers to the amino acid residues of an antibody that are responsible for antigen binding.
  • the hypervariable region comprises amino acid residues from a “complementarity-determining region” or “CDR” (defined by sequence as residues 24-34 (L1), 50-56 (L2) and 89-97 (L3) in the light chain variable domain and 31-35 (H1), 50-65 (H2) and 95-102 (H3) in the heavy chain variable domain; Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md.
  • CDR complementarity-determining region
  • HVL residues can include 26-32 (L1), 50-52 (L2) and 91-96 (L3) in the light chain variable domain and 26-32 (H1), 53-55 (H2) and 96-101 (H3) in the heavy chain variable domain.
  • Antibody fragments may be obtained using conventional recombinant or protein engineering techniques, and the fragments can be screened for binding to NKG2A, or another function, in the same manner as intact antibodies.
  • Antibody fragments of the invention may be made by truncation, e.g. by removal of one or more amino acids from the N and/or C-terminal ends of a polypeptide. Fragments may also be generated by one or more internal deletions.
  • An antibody of the invention may be, or may comprise, a fragment of any anti-NKG2A antibody, the humZ270 antibody (SEQ. ID. NO. 2 and SEQ. ID. NO. 3) or the humZ199 antibody (SEQ. ID. NO. 4 and SEQ. ID. NO. 5) or any other antibody of the invention, or a variant of any one of these antibodies.
  • An antibody of the invention may be, or may comprise, an antigen binding portion of one of these antibodies, or variants thereof.
  • the antibody of the invention may be a Fab fragment of one of these antibodies or variants thereof, or it may be a single chain antibody derived from one of these antibodies, or a variant thereof.
  • An antibody of the invention may be a human antibody or a humanised antibody.
  • the term “human antibody”, as used herein, is intended to include antibodies having variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences. Furthermore, if the antibody contains a constant region, the constant region is also derived from human germline immunoglobulin sequences.
  • the human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo).
  • the term “human antibody”, as used herein is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.
  • Such a human antibody may be a human monoclonal antibody.
  • Such a human monoclonal antibody may be produced by a hybridoma which includes a B cell obtained from a transgenic nonhuman animal, e.g., a transgenic mouse, having a genome comprising a human heavy chain transgene and a light chain transgene fused to an immortalized cell.
  • Human antibodies may be isolated from sequence libraries built on selections of human germline sequences, further diversified with natural and synthetic sequence diversity.
  • Human antibodies may be prepared by in vitro immunisation of human lymphocytes followed by transformation of the lymphocytes with Epstein-Barr virus.
  • human antibody derivatives refers to any modified form of the human antibody, such as a conjugate of the antibody and another agent or antibody.
  • humanized antibody refers to a human/non-human chimeric antibody that contains a minimal sequence (CDR regions) derived from a non-human immunoglobulin.
  • a humanized antibody is, thus, a human immunoglobulin (recipient antibody) in which residues from a hyper-variable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as from a mouse, rat, rabbit, or non-human primate, which have the desired specificity, affinity, and capacity.
  • donor antibody such as from a mouse, rat, rabbit, or non-human primate
  • FR residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • An example of such a modification is the introduction of one or more so-called back-mutations.
  • humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance.
  • a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR residues are those of a human immunoglobulin sequence.
  • the humanized antibody can optionally also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
  • Fc immunoglobulin constant region
  • chimeric antibody refers to an antibody whose light and heavy chain genes have been constructed, typically by genetic engineering, from immunoglobulin variable and constant region genes that originate from different species.
  • variable segments of genes from a mouse monoclonal antibody may be joined to human constant segments.
  • the fragment crystallisable region (“Fc region”/“Fc domain”) of an antibody is the “tail” region of an antibody comprising the constant CH2 and CH3 domains.
  • the Fc domain may interact with cell surface receptors called Fc receptors, as well as some proteins of the complement system.
  • the Fc region enables antibodies to activate the immune system.
  • antibodies may be engineered to include modifications within the Fc region, typically to alter one or more of its functional properties, such as serum half-life, complement fixation, Fc-receptor binding, protein stability and/or antigen-dependent cellular cytotoxicity, or lack thereof.
  • an antibody of the invention may be chemically modified (e.g., one or more chemical moieties can be attached to the antibody) or be modified to alter its glycosylation, again to alter one or more functional properties of the antibody.
  • a modified Fc domain comprises one or more, preferably all of the following mutations that will result in decreased affinity to certain Fc receptors (L234A, L235E, and G237A) and in reduced Clq-mediated complement fixation (A330S and P331S), respectively.
  • the isotype of an antibody of the invention may be IgG, such as IgG1, IgG2, or IgG4.
  • the class of an antibody may be “switched” by known techniques.
  • an antibody that was originally produced as an IgM molecule may be class switched to an IgG antibody.
  • Class switching techniques may also be used to convert one IgG subclass to another, for example: from IgG1 to IgG2 or IgG4; from IgG2 to IgG1 or IgG4; or from IgG4 to IgG1 or IgG2.
  • Engineering of antibodies to generate constant region chimeric molecules, by combination of regions from different IgG subclasses, can also be performed.
  • epitopope is defined in the context of a molecular interaction between an “antigen binding polypeptide”, such as an antibody (Ab), and its corresponding “antigen” (Ag).
  • antigen (Ag) refers to the molecular entity used for immunization of an immunocompetent vertebrate to produce the antibody (Ab) that recognizes the Ag.
  • Ag is termed more broadly and is generally intended to include target molecules that are specifically recognized by the Ab, thus including fragments or mimics of the molecule used in the immunization process for raising the Ab.
  • epitope refers to the area or region on an Ag to which an Ab specifically binds, i.e. the area or region in physical contact with the Ab.
  • a protein epitope may comprise amino acid residues in the Ag that are directly involved in binding to an Ab (also called the immunodominant component of the epitope) and other amino acid residues, which are not directly involved in binding, such as amino acid residues of the Ag which are effectively blocked by the Ab (in other words, the amino acid residue is within the “solvent-excluded surface” and/or the “footprint” of the Ab).
  • NKG2A may comprise a number of different epitopes, which may include, without limitation, (1) linear peptide epitopes, (2) conformational epitopes which consist of one or more non-contiguous amino acids located near each other in the mature NKG2A conformation; and (3) post-translational epitopes which consist, either in whole or part, of molecular structures covalently attached to NKG2A, such as carbohydrate groups.
  • the epitope for a given antibody (Ab)/antigen (Ag) pair can be defined and characterized at different levels of detail using a variety of experimental and computational epitope mapping methods.
  • the experimental methods include mutagenesis, X-ray crystallography, Nuclear Magnetic Resonance (NMR) spectroscopy, Hydrogen deuterium eXchange Mass Spectrometry (HX-MS) and various competition binding methods; methods that are known in the art.
  • NMR Nuclear Magnetic Resonance
  • HX-MS Hydrogen deuterium eXchange Mass Spectrometry
  • each method relies on a unique principle, the description of an epitope is intimately linked to the method by which it has been determined.
  • the epitope for a given Ab/Ag pair will be defined differently.
  • the epitope for the interaction between the Ag and the Ab can be defined by the spatial coordinates defining the atomic contacts present in the Ag-Ab interaction, as well as information about their relative contributions to the binding thermodynamics.
  • the epitope can be characterized by the spatial coordinates defining the atomic contacts between the Ag and Ab.
  • the epitope can be characterized by the amino acid residues that it comprises as defined by a specific criterion such as the distance between atoms in the Ab and the Ag.
  • the epitope can be characterized through function, e.g. by competition binding with other Abs.
  • the epitope can also be defined more generically as comprising amino acid residues for which substitution by another amino acid will alter the characteristics of the interaction between the Ab and Ag.
  • epitope In the context of an X-ray derived crystal structure defined by spatial coordinates of a complex between an Ab, e.g. a Fab fragment, and its Ag, the term epitope is herein, unless otherwise specified or contradicted by context, specifically defined as NKG2A residues characterized by having a heavy atom (i.e. a non-hydrogen atom) within a distance of 4 ⁇ from a heavy atom in the Ab.
  • a heavy atom i.e. a non-hydrogen atom
  • Epitopes described on the amino acid level are said to be identical if they contain the same set of amino acid residues.
  • Epitopes are said to overlap if at least one amino acid is shared by the epitopes.
  • Epitopes are said to be separate (unique) if no amino acid residues are shared by the epitopes.
  • Epitopes characterized by competition binding are said to be overlapping if the binding of the corresponding Abs are mutually exclusive, i.e. binding of one Ab excludes simultaneous binding of the other Ab.
  • the epitopes are said to be separate (unique) if the Ag is able to accommodate binding of both corresponding Abs simultaneously.
  • the definition of the term “paratope” is derived from the above definition of “epitope” by reversing the perspective.
  • the term “paratope” refers to the area or region on the Ab to which an Ag specifically binds, i.e. with which it makes physical contact to the Ag.
  • an X-ray derived crystal structure defined by spatial coordinates of a complex between an Ab, such as a Fab fragment, and its Ag
  • the term paratope is herein, unless otherwise specified or contradicted by context, specifically defined as Ag residues characterized by having a heavy atom (i.e. a non-hydrogen atom) within a distance of 4 ⁇ from a heavy atom in NKG2A.
  • the epitope and paratope for a given antibody (Ab)/antigen (Ag) pair may be identified by routine methods. For example, the general location of an epitope may be determined by assessing the ability of an antibody to bind to different fragments or variant NKG2A polypeptides.
  • the specific amino acids within NKG2A that make contact with an antibody (epitope) and the specific amino acids in an antibody that make contact with NKG2A (paratope) may also be determined using routine methods.
  • the antibody and target molecule may be combined and the Ab/Ag complex may be crystallised. The crystal structure of the complex may be determined and used to identify specific sites of interaction between the antibody and its target.
  • Antibodies binding to the same antigen can be characterized with respect to their ability to bind to their common antigen simultaneously and may be subjected to “binning”.
  • the term “binning” refers to a method of grouping antibodies that bind to the same antigen. “Binning” of antibodies may be based on competition binding of two antibodies to their common antigen in assays based on standard techniques such as Surface Plasmon Resonance (SPR), ELISA or flow cytometry.
  • SPR Surface Plasmon Resonance
  • ELISA ELISA
  • flow cytometry flow cytometry
  • a “bin” is defined by a reference antibody. If a second antibody is unable to bind to the antigen at the same time as the reference antibody, the second antibody is said to belong to the same “bin” as the reference antibody. In this case the reference and the second antibody are competing for binding to the antigen, thus the pair of antibodies are termed “competing antibodies”. If a second antibody is capable of binding to the antigen at the same time as the reference antibody, the second antibody is said to belong to a separate “bin”. In this case the reference and the second antibody are not competing for binding to the antigen, thus the pair of antibodies is termed “non-competing antibodies”.
  • Antibody “binning” does not provide direct information about the epitope. Competing antibodies, i.e. antibodies belonging to the same “bin”, may have identical epitopes, overlapping epitopes or even separate epitopes. The latter is the case if the reference antibody bound to its epitope on the antigen takes up the space required for the second antibody to contact its epitope on the antigen (“steric hindrance”). Non-competing antibodies have separate epitopes.
  • binding affinity is herein used as a measure of the strength of a non-covalent interaction between two molecules, e.g. an antibody, or fragment thereof, and an antigen.
  • binding affinity is used to describe monovalent interactions (intrinsic activity).
  • Binding affinity between two molecules, e.g. an antibody, or fragment thereof, and an antigen, through a monovalent interaction may be quantified by determination of the dissociation constant (K D ).
  • K D can be determined by measurement of the kinetics of complex formation and dissociation, e.g. by the SPR method.
  • the rate constants corresponding to the association and the dissociation of a monovalent complex are referred to as the association rate constant k a (or k on ) and dissociation rate constant k d (or k off ), respectively.
  • binding affinities associated with different molecular interactions such as comparison of the binding affinity of different antibodies for a given antigen, may be compared by comparison of the K D values for the individual antibody/antigen complexes.
  • the specificity of an interaction may be assessed by determination and comparison of the K D value for the interaction of interest, such as a specific interaction between an antibody and an antigen, with the K D value of an interaction not of interest.
  • the K D for the antibody with respect to the target will be 2-fold, preferably 5-fold, more preferably 10-fold less than K D with respect to the other, non-target molecule such as unrelated material or accompanying material in the environment. More preferably, the K D will be 50-fold less, such as 100-fold less, or 200-fold less; even more preferably 500-fold less, such as 1,000-fold less, or 10,000-fold less.
  • this dissociation constant can be determined directly by well-known methods, such as by standard assays to evaluate the binding ability of ligands such as antibodies towards targets which are known in the art and include, for example, ELISAs, Western blots, RIAs, and flow cytometry analysis.
  • the binding kinetics and binding affinity of the antibody can also be assessed by standard assays known in the art, such as SPR.
  • a competitive binding assay can be conducted in which the binding of the antibody to the target is compared to the binding of the target by another ligand of that target, such as another antibody.
  • An antibody of the invention may have a K D for its target of 1 ⁇ 10 ⁇ 7 M or less, 1 ⁇ 10 ⁇ 8 M or less, 1 ⁇ 10 ⁇ 9 M or less, 1 ⁇ 10 ⁇ 10 M or less, 1 ⁇ 10 ⁇ 11 M or less, or 1 ⁇ 10 ⁇ 12 M or less.
  • the K D of an antibody of the current invention may be less than 0.8 nM, such as less than 0.7 nM, less than 0.6 nM, less than 0.5 nM, less than 0.4 nM, less than 0.3 nM, less than 0.2 nM, less than 0.1 nM, less than 0.05 nM, less than 0.025 nM, or less than 0.015 nM, such as between 0.015 nM and 0 nM.
  • identity refers to a relationship between the sequences of two or more polypeptides, as determined by comparing the sequences.
  • identity also means the degree of sequence relatedness between polypeptides, as determined by the number of matches between strings of two or more amino acid residues. “Identity” measures the percent of identical matches between the smaller of two or more sequences with gap alignments (if any) addressed by a particular mathematical model or computer program (i.e., “algorithms”). Identity of related polypeptides can be readily calculated by known methods. Such methods include, but are not limited to, those described in Computational Molecular Biology, Lesk, A.
  • Preferred methods for determining identity are designed to give the largest match between the sequences tested. Methods of determining identity are described in publicly available computer programs. Preferred computer program methods for determining identity between two sequences include the GCG program package, including GAP (Devereux et al., Nucl. Acid. Res. 12, 387 (1984); Genetics Computer Group, University of Wisconsin, Madison, Wis.), BLASTP, BLASTN, and FASTA (Altschul et al., J. Mol. Biol. 215, 403-410 (1990)). The BLASTX program is publicly available from the National Center for Biotechnology Information (NCBI) and other sources (BLAST Manual, Altschul et al. NCB/NLM/NIH Bethesda, Md. 20894; Altschul et al., supra). The well-known Smith Waterman algorithm may also be used to determine identity.
  • NCBI National Center for Biotechnology Information
  • GAP Genetics Computer Group, University of Wisconsin, Madison, Wis.
  • two polypeptides for which the percent sequence identity is to be determined are aligned for optimal matching of their respective amino acids (the “matched span”, as determined by the algorithm).
  • a gap opening penalty (which is calculated as 3 times the average diagonal; the “average diagonal” is the average of the diagonal of the comparison matrix being used; the “diagonal” is the score or number assigned to each perfect amino acid match by the particular comparison matrix) and a gap extension penalty (which is usually 1/10 times the gap opening penalty), as well as a comparison matrix such as PAM 250 or BLOSUM 62 are used in conjunction with the algorithm.
  • a standard comparison matrix see Dayhoff et al., Atlas of Protein Sequence and Structure, vol.
  • Preferred parameters for a peptide sequence comparison include the following:
  • the GAP program is useful with the above parameters.
  • the aforementioned parameters are the default parameters for peptide comparisons (along with no penalty for end gaps) using the GAP algorithm.
  • similarity is a related concept, but in contrast to “identity”, refers to a sequence relationship that includes both identical matches and conservative substitution matches. If two polypeptide sequences have, for example, (fraction ( 10/20)) identical amino acids, and the remainder are all non-conservative substitutions, then the percent identity and similarity would both be 50%. If, in the same example, there are 5 more positions where there are conservative substitutions, then the percent identity remains 50%, but the percent similarity would be 75% (fraction ( 15/20)). Therefore, in cases where there are conservative substitutions, the degree of similarity between two polypeptides will be higher than the percent identity between those two polypeptides.
  • a “receptor” is defined as a molecular structure present on the surface or inside of a cell.
  • a receptor produces a characteristic cellular response, i.e. biological activity, when a ligand binds.
  • a “ligand” for a receptor is defined as any molecule (e.g. peptide, polypeptide, carbohydrate, small molecule or ion) that selectively is capable of binding to the receptor.
  • An agonistic ligand (“agonist”) is a ligand that upon binding to the receptor to some degree is capable of eliciting the characteristic response for the receptor.
  • An antagonistic ligand (“antagonist”) is a ligand that has the ability to bind to the receptor and to some degree block the action of an agonist, e.g. the natural ligand of the receptor.
  • NKG2A (OMIM 161555, the entire disclosure of which is herein incorporated by reference) is a member of the NKG2 group of transcripts (Houchins, et al. (1991) J. Exp. Med. 173:1017-1020). NKG2A is encoded by 7 exons spanning 25 kb, showing some differential splicing. Together with CD94, NKG2A forms the heterodimeric inhibitory receptor CD94/NKG2A, found on the surface of subsets of NK cells, ⁇ / ⁇ T cells, ⁇ / ⁇ T cells, and NKT cells. Similar to inhibitory KIR receptors, it possesses an ITIM in its cytoplasmic domain.
  • NKG2A refers to any variant, derivative, or isoform of the NKG2A gene or encoded protein. Also encompassed are any nucleic acid or protein sequences sharing one or more biological properties or functions with wild type, full length NKG2A, and sharing at least 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or higher nucleotide or amino acid identity.
  • Human NKG2A comprises 233 amino acids in 3 domains, with a cytoplasmic domain comprising residues 1-70, a transmembrane region comprising residues 71-93, and an extracellular region comprising residues 94-233, of the following sequence:
  • HLA-E (OMIM 143010, the entire disclosure of which is herein incorporated by reference) is a nonclassical MHC molecule that is expressed on the cell surface and regulated by the binding of peptides derived from the signal sequence of other MHC class I molecules.
  • HLA-E binds natural killer (NK) cells and some T cells, binding specifically to CD94/NKG2A, CD94/NKG2B, and CD94/NKG2C (see, e.g., Braud et al. (1998) Nature 391:795-799, the entire disclosure of which is herein incorporated by reference).
  • Surface expression of HLA-E is sufficient to protect target cells from lysis by CD94/NKG2A+NK, T, or NKT cell clones.
  • HLA-E refers to any variant, derivative, or isoform of the HLA-E gene or encoded protein. Also encompassed are any nucleic acid or protein sequences sharing one or more biological properties or functions with wild type, full length HLA-E, and sharing at least 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or higher nucleotide or amino acid identity.
  • an agent that binds to human CD94/NKG2A receptor or “an anti-NKG2A antibody” or “NKG2A binding antibody” refers to an any agent and/or antibody with detectable binding to human CD94/NKG2A receptor using any standard assay where the agent and/or antibody is incubated in the presence of CD94/NKG2A or NKG2A and binding detected via, e.g., radiolabels, physical methods such as mass spectrometry, or direct or indirect fluorescent labels detected using, e.g., cytofluorometric analysis (e.g. FACScan). Any amount of binding above the amount seen with a control, non-specific agent indicates that the agent binds to the target.
  • cytofluorometric analysis e.g. FACScan
  • humanized Z270 or humZ270 or hZ270 comprises the antibody (SEQ. ID. NO. 2 and SEQ. ID. NO. 3) disclosed in the patent publication WO08009545, which is hereby incorporated by reference into this application.
  • humanized Z199 or humZ199 comprises the antibody (SEQ. ID. NO. 4 and SEQ. ID. NO. 5) disclosed in the patent publication WO09092805 which is hereby incorporated by reference into this application.
  • “Protractive groups”/“half-life extending moieties” are herein understood as one or more chemical groups attached to one or more amino acid site chain functionalities such as —SH, —OH, —COOH, —CONH2, —NH2, or one or more N- and/or O-glycan structures and that can increase in vivo circulatory half-life of therapeutic proteins/peptides when conjugated to these proteins/peptides.
  • “protractive groups” include but are not limited to: Biocompatible fatty acids and derivatives thereof, Hydroxyalkyl Starch (HAS) e.g.
  • HES Hydroxyethyl Starch
  • PEG Polyethylene Glycol
  • HAP Poly (Glyx-Sery)n
  • HAP Hyaluronic acid
  • HEP Heparosan polymers
  • PC polymer Phosphorylcholine-based polymers
  • Fleximers Dextran
  • Polysialic acids PSA
  • Fc domain Transferrin
  • Albumin Elastin-like peptides
  • XTEN polymers Albumin binding peptides
  • CTP peptide CTP peptide, and any combination thereof.
  • NKG2A Fc fusion protein is herein meant to encompass NKG2A fused to an Fc domain that can be derived from any antibody isotype.
  • Inflammation is the complex biological response of tissues to a variety of stimuli, including pathogens, damaged cells, or irritants. Inflammation is a protective response by the organism to remove or isolate the injurious stimuli and initiate the healing process. Inflammation is not a synonym for infection-infection is invasion of an organism by an exogenous pathogen, while inflammation is the immune system's response to the pathogen.
  • Inflammation is a cascade of events involving multiple components, including the vasculature (e.g., endothelial cells, pericytes, smooth muscle cells), cells of the immune system (e.g., T and B lymphocytes, monocytes, dendritic cells, neutrophils), cell-derived soluble mediators (cytokines, chemokines) and also resident cells in the targeted tissue (e.g., epithelial cells, synovial fibroblasts, neuronal cells).
  • vasculature e.g., endothelial cells, pericytes, smooth muscle cells
  • cells of the immune system e.g., T and B lymphocytes, monocytes, dendritic cells, neutrophils
  • cytokines, chemokines cell-derived soluble mediators
  • Acute inflammation is of short duration (hours to days) and largely involves resident cells in tissue, migration of leukocytes and exudation of fluid and plasma proteins to site of inflammation.
  • Chronic inflammation is of prolonged duration in which active inflammation, tissue destruction and attempt at repair proceed simultaneously.
  • Chronic inflammation can result from persistent infection, prolonged and repeated exposure to toxic agents or autoimmunity, a phenomenon by which the body's immune cells attack their own tissues, causing damage.
  • the immune system is able to distinguish between the body's normal cells (or “self”) and foreign pathogens or abnormal cells (“non-self”). In some instances, the immune system loses the ability to recognize “self” as normal and inappropriately initiates a response against tissue or cells. This response stems from a loss of tolerance to self and is termed “autoimmunity”.
  • autoimmunity The pathologies resulting from autoimmunity often have serious clinical consequences and are one of the major health problems in the world, especially in developed nations.
  • autoimmune diseases include rheumatoid arthritis (RA), psoriasis, psoriatic arthritis, systemic lupus erythematosus (SLE), lupus nephritis, type I diabetes, Graves' disease, inflammatory bowel disease (IBD), Crohn's disease (CD), ulcerative colitis (UC), irritable bowel syndrome, multiple sclerosis (MS), autoimmune myocarditis, Kawasaki disease, coronary artery disease, chronic obstructive pulmonary disease, interstitial lung disease, autoimmune thyroiditis, scleroderma, systemic sclerosis, osteoarthritis, atopic dermatitis, vitiligo, graft vs. host disease, Sjören's syndrome, autoimmune nephritis, Goodpasture syndrome, chronic inflammatory demyelinating polyneuropathy, allergy, asthma and other autoimmune diseases that are a result of either acute or chronic inflammation.
  • RA rhe
  • Targeted biological therapeutics are now available for the treatment of certain autoimmune diseases and/or chronic inflammatory diseases.
  • patients with rheumatoid arthritis may be treated with anti-CD20, a TNF antagonist (soluble TNFR or anti-TNF- ⁇ ); patients with psoriasis may be treated with anti-CD11a; patients with multiple sclerosis may be treated with INF-beta; patients with ulcerative colitis may be treated with anti-TNF- ⁇ ; and patients with Crohn's disease may be treated with anti-TNF- ⁇ or anti-CD4 integrin.
  • a large number of patients that receive treatment with any one of these biologics can experience a variety of side effects, could fail to respond, and/or can develop neutralizing antibodies against the drug.
  • the current invention relates to these unmet needs amongst patients with autoimmune and/or chronic inflammatory diseases, disclosing antibodies that are suitable for use in such treatment.
  • RA Rheumatoid arthritis
  • RA Rheumatoid arthritis
  • inflammation of the joints which causes pain, stiffness, warmth, redness and swelling.
  • This inflammation is a consequence of inflammatory cells invading the joints and releasing enzymes that may digest bone and cartilage.
  • This inflammation can lead to severe bone and cartilage damage and to joint deterioration and severe pain among other physiological effects.
  • the involved joint can lose its shape and alignment, resulting in pain and loss of movement.
  • rheumatoid arthritis There are several animal models for rheumatoid arthritis known in the art. For example, in the collagen-induced arthritis (CIA) model, mice develop an inflammatory arthritis that resembles human rheumatoid arthritis. Since CIA shares similar immunological and pathological features with RA, this makes it a suitable model for screening potential human anti-inflammatory compounds. Efficacy in this model is measured by decrease in joint swelling. Efficacy in RA in the clinic is measured by the ability to reduce symptoms in patients which is measured as a combination of joint swelling, erythrocyte sedimentation rate, C-reactive protein levels and levels of serum factors.
  • CIA collagen-induced arthritis
  • FLS Fibroblast-like synoviocytes
  • RASF RA synovial fibroblasts
  • RS RA synovial fibroblasts
  • Cartilage erosion or cartilage destruction is the loss or degradation of the cartilage tissue.
  • Bone resorption the removal of osseous tissue by osteoclasts, is the unique function of the osteoclasts, which are specialized multinucleated cells derived from the monocyte cell lineage. Their differentiation is regulated by macrophage colony-stimulating factor, RANK ligand, and osteoprotegerin as well as multiple other mediators that may either positively or negatively regulate their differentiation, activation, and/or survival.
  • the osteoclast develops a specialized cytoskeleton that permits it to establish an isolated microenvironment between itself and bone, wherein degradation of bone protein and minerals occurs by a process involving proton transport and enzyme release.
  • Bone erosion is the loss of bone mass or bone mineral density that happens when there is a slight (or more than slight) but persistent elevation in the rate of bone resorption over the rate of bone formation.
  • Osteoarthritis is the most prevalent type of arthritis, particularly in adults 65 years and older. The disease is characterized by chronic degenerative arthropathy that frequently leads to chronic pain and disability. The reported incidence and prevalence rates of OA in specific joints vary widely, due to differences in the case definition of OA.
  • OA may be defined by radiographic criteria alone (radiographic OA), by typical symptoms (symptomatic OA), or by both. Using radiographic criteria, the distal and proximal interphalangeal joints of the hand have been identified as the joints most commonly affected, but they are the least likely to be symptomatic. In contrast, the knee and hip, which constitute the second and third most common locations of radiographic OA, respectively, are nearly always symptomatic.
  • the first metatarsal phalangeal and carpometacarpal joints are also frequent sites of radiographic OA, while the shoulder, elbow, wrist and metacarpophalangeal joints rarely develop idiopathic OA.
  • Age is the most consistently identified risk factor for OA and prevalence rates rise steeply after age 50 in men and age 40 in women.
  • OA is diagnosed by a triad of typical symptoms, physical findings and radiographic changes.
  • the American College of Rheumatology has set forth classification criteria to aid in the identification of patients with symptomatic OA that include, but do not rely solely on, radiographic findings.
  • Patients with early disease experience localized joint pain that worsens with activity and is relieved by rest, while those with severe disease may have pain at rest. Weight bearing joints may “lock” or “give way” due to internal derangement that is a consequence of advanced disease. Stiffness in the morning or following inactivity (“gel phenomenon”) rarely exceeds 30 minutes.
  • Radiographic findings in osteoarthritic joints include bony enlargement, crepitus, cool effusions, and decreased range of motion. Tenderness on palpation at the joint line and pain on passive motion are also common, although not unique to OA.
  • Radiographic findings in OA include osteophyte formation, joint space narrowing, subchondral sclerosis and cysts. The presence of an osteophyte is the most specific radiographic marker, although it is indicative of relatively advanced disease.
  • Radiographs are considered the “gold standard” test for the diagnosis of OA, but radiographic changes are evident only relatively late in the disease. The need is great for a sensitive and specific biological marker that would enable early diagnosis of OA, and monitoring of its progression. Routine laboratory studies, such as sedimentation rates and c-reactive protein, are not useful as markers for OA, although a recent study suggests that elevation of CRP predicts more rapidly progressive disease.
  • Several epitopes of cartilage components have been described that offer some promise as markers of OA. For example, chondroitin sulfate epitope 846, normally expressed only in fetal and neonatal cartilage, has been observed in OA, but not normal adult, cartilage and synovial fluid.
  • an epitope unique to type II collagen has been described in OA cartilage, and can be unmasked in vitro by exposing normal cartilage to MMPs. This epitope can be measured in blood and urine and may prove useful in diagnosing or monitoring OA progression. Elevated serum hyaluronan levels have also been shown by some to correlate with radiographic OA. The finding of elevated cartilage oligomeric protein (COMP) levels in synovial fluid after traumatic joint injury may portend development of OA in the injured joint.
  • Other potential markers of OA are listed but are either not easily accessible or lack the sensitivity and specificity required to consider them as potential OA markers.
  • Psoriatic arthritis is a type of inflammatory arthritis that occurs in a subset of patients with psoriasis. In these patients, the skin pathology/symptoms are accompanied by joint swelling, similar to that seen in rheumatoid arthritis. It features patchy, raised, red areas of skin inflammation with scaling. Psoriasis often affects the tips of the elbows and knees, the scalp, the navel, and around the genital areas or anus.
  • psoriatic arthritis denotes a heterogeneous group of arthritides ranging from peripheral monoarticular, oligoarticular and polyarticular disease, to axial skeletal involvement. Yet, despite this apparent clinical heterogeneity, these various presentations are unified in their occurrence in individuals with cutaneous manifestations of psoriasis, rheumatoid factor sero-negativity, similar human leukocyte antigen (HLA) associations and radiographic similarities.
  • HLA human leukocyte antigen
  • Streptococcal infection can precipitate the development of guttate psoriasis. HIV infection can present with both psoriasis and psoriatic arthritis, as well as worsen existing disease. Physical trauma has been reported to precipitate the development of arthritis, suggesting that psoriatic arthritis is the manifestation of a “deep Koebner phenomenon”. The inflammatory and autoimmune character of the disease is supported not only by the clinical presentation, but also by the role that T-cells and various cytokines have been demonstrated to play in both the initiation and perpetuation of disease activity.
  • Factors that may portend a worse prognosis include extensive skin involvement; a strong family history of psoriasis; female gender; disease onset at ⁇ 20 years of age; expression of HLA-B27, -DR3 or -DR4 alleles; and polyarticular or erosive disease.
  • Osteoporosis is a disease of bones that leads to an impaired bone strength and increased risk of fracture (see e.g. Theill et al. (2002) Annu Rev Immunol 20:795-23).
  • BMD bone mineral density
  • WHO World Health Organization
  • the disease is defined by a bone mineral density that is 2.5 standard deviations or more below the mean peak bone mass (average of young, healthy adults).
  • the disease may be classified as primary type 1, primary type 2, or secondary.
  • the form of osteoporosis most common in women after menopause is referred to as primary type 1 or postmenopausal osteoporosis.
  • Bone resorption is a major pathological factor in postmenopausal osteoporosis. Rapid or relatively rapid loss of bone mass/bone mineral density is often caused by an increase in number of osteoclasts or by excessive osteoclast activity (Walsh et al. (2005) Immunol Rev 208:228-251).
  • Osteoporosis risks can be reduced with lifestyle changes (e.g. diet, exercise, fall prevention) and sometimes medication (e.g. calcium, vitamin D, bisphosphonates and several others).
  • lifestyle changes e.g. diet, exercise, fall prevention
  • medication e.g. calcium, vitamin D, bisphosphonates and several others.
  • treatment refers to the medical therapy of any human. Said subject is expected to have undergone physical examination by a medical practitioner, who has given a tentative or definitive diagnosis which would indicate that the use of said specific treatment is beneficial to the health of said human subject.
  • the timing and purpose of said treatment may vary from one individual to another, according to the status quo of the subject's health.
  • said treatment may be prophylactic, palliative, symptomatic and/or curative.
  • prophylactic, palliative, symptomatic and/or curative treatments may represent separate aspects of the invention.
  • the present invention provides compositions and formulations comprising molecules of the invention, such as the antibodies, antigen binding fragments of antibodies, polynucleotides, vectors and cells described herein.
  • the invention provides a pharmaceutical composition that comprises one or more antibody or antigen binding fragment of antibodies of the invention, formulated together with a pharmaceutically acceptable carrier.
  • one object of the invention is to provide a pharmaceutical formulation comprising such an antibody which is present in a concentration from 0.25 mg/ml to 250 mg/ml, and wherein said formulation has a pH from 2.0 to 10.0.
  • the formulation may further comprise a buffer system, preservative(s), tonicity agent(s), chelating agent(s), stabilizers and surfactants.
  • preservatives tonicity agent(s)
  • chelating agent(s) chelating agent(s)
  • stabilizers and surfactants The use of preservatives, isotonic agents, chelating agents, stabilizers and surfactants in pharmaceutical compositions is well-known to the skilled person. Reference may be made to Remington: The Science and Practice of Pharmacy, 19th edition, 1995.
  • the pharmaceutical formulation is an aqueous formulation.
  • aqueous formulation is defined as a formulation comprising at least 50% w/w water.
  • aqueous solution is defined as a solution comprising at least 50% w/w water, and the term “aqueous suspension” is defined as a suspension comprising at least 50% w/w water.
  • the pharmaceutical formulation is a freeze-dried formulation, to which the physician or the patient adds solvents and/or diluents prior to use.
  • the pharmaceutical formulation comprises an aqueous solution of such an antibody, and a buffer, wherein the antibody is present in a concentration from 1 mg/ml or above, and wherein said formulation has a pH from about 2.0 to about 10.0.
  • An antibody of the invention may be administered parenterally, such as intravenously, such as intramuscularly, such as subcutaneously.
  • an antibody of the invention may be administered via a non-parenteral route, such as perorally or topically.
  • An antibody of the invention may be administered prophylactically.
  • An antibody of the invention may be administered therapeutically (on demand).
  • selective elimination of cartilage destructive cells refers to a process in which an antibody against NKG2A increases NK cell mediated elimination of cartilage destructive cells, such as fibroblast-like synoviocytes (FLS) or other cartilage destructive cells, while not increasing the elimination of normal fibroblasts, such as e.g. foreskin fibroblasts (FSK4 cells) or other normal fibroblast cells.
  • This selective elimination can be measured for example by a standard LDH release assay or other known suitable assays, in which the capacity of the therapeutic compound to eliminate the cartilage destructive cells is measured (see Example 4 and FIG. 5 B ).
  • an anti-NKG2A antibody causes at least 5% increase in the specific cytotoxicity of the cartilage destructive cells, or at least 10% increase in the specific cytotoxicity of the cartilage destructive cells. In one embodiment, an anti-NKG2A antibody causes at least 20% increase in the specific cytotoxicity of the cartilage destructive cells, or at least 30% increase in the specific cytotoxicity of the cartilage destructive cells. In one embodiment, an anti-NKG2A antibody causes at least 40% increase in the specific cytotoxicity of the cartilage destructive cells, or at least 50% increase in the specific cytotoxicity of the cartilage destructive cells.
  • an anti-NKG2A antibody causes at least 60% increase in the specific cytotoxicity of the cartilage destructive cells, or at least 70% increase in the specific cytotoxicity of the cartilage destructive cells. In one embodiment, an anti-NKG2A antibody causes at least 80% increase in the specific cytotoxicity of the cartilage destructive cells, or at least 90% increase in the specific cytotoxicity of the cartilage destructive cells. In one embodiment, an anti-NKG2A antibody causes at least 100% increase in the specific cytotoxicity of the cartilage destructive cells, or at least 125% increase in the specific cytotoxicity of the cartilage destructive cells.
  • an anti-NKG2A antibody causes at least 150% increase in the specific cytotoxicity of the cartilage destructive cells, or at least 175% increase in the specific cytotoxicity of the cartilage destructive cells. In one embodiment, an anti-NKG2A antibody causes at least 200% increase in the specific cytotoxicity of the cartilage destructive cells, or at least 225% increase in the specific cytotoxicity of the cartilage destructive cells. In one embodiment, an anti-NKG2A antibody causes at least 250% increase in the specific cytotoxicity of the cartilage destructive cells, or at least 275% increase in the specific cytotoxicity of the cartilage destructive cells.
  • an anti-NKG2A antibody causes at least 300% increase in the specific cytotoxicity of the cartilage destructive cells, or at least 350% increase in the specific cytotoxicity of the cartilage destructive cells. In one embodiment, an anti-NKG2A antibody causes at least 400% increase in the specific cytotoxicity of the cartilage destructive cells, or at least 500% increase in the specific cytotoxicity of the cartilage destructive cells.
  • “reduces formation of bone eroding cells” refers to a process in which an anti-NKG2A antibody reduces the formation of bone eroding cells, such as osteoclasts, TRAP+ multinucleated cells or other bone eroding cells.
  • the reduced formation of bone eroding cells can be measured in vitro by visual counting of adherent bone eroding cells (see Example 6. and FIG. 6 C .) or any other suitable method of measuring the reduced formation of the bone eroding cells.
  • an anti-NKG2A antibody causes at least 5% reduction of bone eroding cells or at least 10% reduction of bone eroding cells.
  • an anti-NKG2A antibody causes at least 20% reduction of bone eroding cells or at least 30% reduction of bone eroding cells.
  • an anti-NKG2A antibody causes at least 40% reduction of bone eroding cells or at least 50% reduction of bone eroding cells.
  • an anti-NKG2A antibody causes at least 60% reduction of bone eroding cells or at least 70% reduction of bone eroding cells. In one embodiment an anti-NKG2A antibody causes at least 80% reduction of bone eroding cells or at least 90% reduction of bone eroding cells. In one embodiment an anti-NKG2A antibody causes at least 100% reduction of bone eroding cells or at least 125% reduction of bone eroding cells. In one embodiment an anti-NKG2A antibody causes at least 150% reduction of bone eroding cells or at least 175% reduction of bone eroding cells. In one embodiment an anti-NKG2A antibody causes at least 200% reduction of bone eroding cells or at least 225% reduction of bone eroding cells.
  • an anti-NKG2A antibody causes at least 250% reduction of bone eroding cells or at least 275% reduction of bone eroding cells. In one embodiment an anti-NKG2A antibody causes at least 300% reduction of bone eroding cells or at least 350% reduction of bone eroding cells. In one embodiment an anti-NKG2A antibody causes at least 400% reduction of bone eroding cells or at least 450% reduction of bone eroding cells. In one embodiment an anti-NKG2A antibody causes at least 500% reduction of bone eroding cells.
  • the reduced in vitro bone mineral erosion can be measured by culturing the cells or tissue on bone mineral discs (i.e. osteologic discs) or by other suitable methods. (See Example 6. and FIGS. 6 D, 6 E, 6 F and 6 G ).
  • an anti-NKG2A causes a 10% reduction in bone mineral erosion or 20% reduction in bone mineral erosion.
  • an anti-NKG2A causes a 30% reduction in bone mineral erosion or 40% reduction in bone mineral erosion.
  • an anti-NKG2A causes a 50% reduction in bone mineral erosion or 60% reduction in bone mineral erosion.
  • an anti-NKG2A causes a 70% reduction in bone mineral erosion or 80% reduction in bone mineral erosion.
  • an anti-NKG2A causes a 90% reduction in bone mineral erosion or 100% reduction in bone mineral erosion. In one embodiment an anti-NKG2A causes a 125% reduction in bone mineral erosion or 150% reduction in bone mineral erosion. In one embodiment an anti-NKG2A causes a 175% reduction in bone mineral erosion or 200% reduction in bone mineral erosion. In one embodiment an anti-NKG2A causes a 250% reduction in bone mineral erosion or 300% reduction in bone mineral erosion. In one embodiment an anti-NKG2A causes a 350% reduction in bone mineral erosion or 400% reduction in bone mineral erosion. In one embodiment an anti-NKG2A causes a 450% reduction in bone mineral erosion or 500% reduction in bone mineral erosion. In one embodiment an anti-NKG2A causes a 550% reduction in bone mineral erosion or 600% reduction in bone mineral erosion. In one embodiment an anti-NKG2A causes a 650% reduction in bone mineral erosion or 700% reduction in bone mineral erosion.
  • FIG. 1 A adherent RA-FLS derived from RA synovial tissue were detached using 2 mM EDTA and surface stained for expression of fibroblast-marker CD55 (open histogram; right panel) and macrophage-marker CD68 (open histogram; left panel).
  • the gray histogram represents the staining using an isotype control antibody.
  • the RA-FLS show homogenous expression of CD55 and lack of CD68 confirms the fibroblast-like origin of adherent RA-FLS.
  • RA-FLS express high levels of ULBP-1, ULBP-2 and ULBP3, low levels of MIC-A, and no MIC-B, all known ligands for the activating NK cell receptor NKG2D. Furthermore, RA-FLS express CD155 (poliovirus receptor PVR) and CD48, ligands for DNAM-1 and 2B4, respectively. We did not detect any expression of CD112 (poliovirus-related receptor 2, PRR2), another ligand recognized by DNAM-1.
  • CD155 poliovirus receptor PVR
  • CD48 ligands for DNAM-1 and 2B4
  • NKp30-Fc and NKp46-Fc failed to stain these cells.
  • Cells were analyzed by flow cytometry. Filled histograms represent relevant isotype control. Histograms are representative for n ⁇ 3 donors.
  • FIG. 1 C illustrates that the binding of soluble NKp44-Fc fusion protein to RA-FLS was specific and abolished by the addition of increasing doses of anti-NKp44 mAb.
  • Adherent RA-FLS were detached using 2 mM EDTA, and surface stained with 10 ug/mL NKp44-Fc fusion protein (open histogram) or the same Fc fragment (human IgG1) as a negative control (gray histogram). Where indicated, NKp44-Fc was pre-incubated with anti-NKp44 or anti-NKp46 mAbs.
  • RA-FLS express high levels of both HLA-E and HLA-G, ligands for the inhibitory NK cell receptors CD94-NKG2A and LIR-1, respectively.
  • HLA-E may be an important molecule protecting RA-FLS from NK cell-mediated cytotoxicity in the inflamed synovium, as most synovial NK cells express the inhibitory CD94-NKG2A receptor.
  • RA-FLS express death receptor 5 (DR5) but not DR4. These receptors transduce apoptotic signals upon recognition by TRAIL (TNF-related apoptosis-inducing ligand).
  • TRAIL TNF-related apoptosis-inducing ligand
  • DR5 may be an important ligand expressed on RA-FLS that can be recognized by TRAIL expressing cells that potentially can mediate RA-FLS cell death within the inflamed synovial tissue.
  • Example 2 NKG2A Expressing NK Cells are Present in RA Synovium and can be Found in Areas Containing HLA-E Expressing RA-FLS
  • FIGS. 2 A, 2 B, and 2 C shows serial synovial tissue sections derived from a patient with RA stained with mouse anti-NKp46 (NK cells, FIG. 2 A ), anti-NKG2A ( FIG. 2 B ) and isotype control antibody ( FIG. 2 C ). Immune-specific reactivity was visualized with diaminobenzidine (dark spots in the micrograph) and nuclei were counterstained with hematoxylin (faint spots). The results show that NKp46+NK cells are found in the sublining area and a few closer to the synovial lining of RA synovium (see FIG. 2 A ). Localization and frequency of NK cells were found to be very similar to that of NKG2A+ cells (see FIG.
  • HLA-E the ligand for CD94-NKG2A
  • FIGS. 2 E-H The expression of HLA-E, the ligand for CD94-NKG2A, on RA-FLS was evaluated in situ ( FIGS. 2 E-H ).
  • both infiltrating immune cells shown in FIG. 2 F .
  • vascular endothelial cells as shown in FIG. 2 H . expressed HLA-E at relatively high levels.
  • NK cells can be identified among the infiltrating lymphocyte population in the synovium of RA patients, and suggest that most, if not all, NK cells express NKG2A. Furthermore, subsets of NKG2A+NK cells are found in areas close to HLA-E+ RA-FLS. Thus, this could potentially mean that NKG2A+NK cells recognize HLA-E on RA-FLS in situ.
  • Example 3 NKG2D, DNAM-1, NKp44, NKp46, and TRAIL are Involved in NK Cell Cytotoxicity Towards RA-FLS
  • FIG. 3 A three different types of NK cells that were stained for surface expression of several NK cell receptors are shown (as open histogram), as indicated below each histogram, and staining with a relevant isotype control is also shown in each panel (filled gray histogram).
  • FIG. 3 A shows NK cells derived from SFMC from a representative RA patient
  • FIG. 3 A shows resting CD56bright NK cells derived from PBMC from a representative healthy donor
  • FIG. 3 A shows Nishi NK cells.
  • NK cells were defined as viable CD3-CD56bright. The data shows that synovial NK cells derived from RA patients express several activating receptors, and that they show a similar expression pattern of activating receptors to CD56bright NK cells and Nishi NK cells.
  • FIG. 3 B (i) illustrates RA-FLS that were seeded at 10,000 cells/well in 48-well plates, and grown to confluency ( ⁇ 48,000 cells/well) for 72 hours, at which point Nishi were added at the indicated effector:target (E:T) ratios (duplicate wells were set up).
  • RA-FLS and Nishi were co-cultured overnight at 37° C., non-adherent cells were subsequently washed off and adherent cells were fixed with 4% paraformaldehyde and stained with Eosin.
  • An ImmunoSpot Image Analyzer was used to take images and quantify the % well area covered (as shown in FIG. 3 B . (ii)).
  • FIG. 3 B (i) and 3B(ii) shows that NK cells eliminate plastic-adherent RA-FLS in a dose-dependent manner in vitro.
  • FIG. 3 C shows that NK cells only degranulate in the presence of FLS target cells and not when cultured alone.
  • FIG. 3 D shows that RA-FLS are sensitive to NK cell-mediated cytotoxicity, and that NKG2D, DNAM1, NKp44, NKp46 and TRAIL are all involved in the specific recognition of RA-FLS by NK cells as indicated by a significant reduction in CD107a/b expression upon masking such receptors.
  • RA-FLS are Protected from NK Cell-Mediated Cytotoxicity by Expression of HLA-E Capable of Interacting with Inhibitory CD94-NKG2A Receptors Expressed by NK Cells
  • FIG. 4 A shows representative histograms with NK cells from RA-SFMC in the top row, resting CD56bright NK cells from healthy PBMC in the middle row and Nishi NK cells in the bottom row.
  • Expression of NKG2A (left column), LIR-1 (middle column) and KIRs (right column) is shown (open histograms) compared with corresponding isotype control (gray filled histograms).
  • NK cells were stained for surface expression using anti-NKG2A, anti-LIR1, and a cocktail of anti-KIR mAbs and subsequently analyzed by flow cytometry. NK cells are gated on viable CD3 negative CD56bright positive cells.
  • Nishi NK cells similar to Nishi NK cells and CD56bright PB-NK cells express NKG2A but lack KIRs. In contrast to synovial fluid NK cells, Nishi NK cells also express LIR-1.
  • FIG. 4 C demonstrates RA-FLS that were seeded at 2.4 ⁇ 10 4 cells/well in 96-well plates; the following day 6-103 Nishi NK cells/well were added (i.e. E:T of 1:4). FLS and Nishi were co-cultured overnight with the addition of anti-NKG2A or human IgG4 isotype control. The next day, non-adherent cells were washed off, adherent cells were fixed with 4% paraformaldehyde and stained with Eosin. Wells were analyzed, and % well area covered was quantified, using an ImmunoSpot Image Analyzer, as shown in FIG. 4 C . Thus, the data show that masking NKG2A results in a significantly increased elimination of adherent RA-FLS.
  • RA-FLS were seeded at 1.5 ⁇ 10 4 cells/well in 96-well plates; the following day 4.5 ⁇ 10 4 autologous SFMC were added per well (i.e. E:T 3:1). SFMC and RA-FLS were co-cultured for 5 hours at 37° C. with BD GolgiStop, FITC-conjugated anti-CD107a/b antibodies and 10 ug/mL blocking antibodies, or human IgG4 isotype control, as shown in FIG. 4 D .
  • FIG. 4 E shows 3-104 FLS/well that were seeded in 96-well plates.
  • allogeneic CD56brightCD16dim NK cells were isolated from healthy donor blood by magnetic separation and immediately co-cultured with RA-FLS (E:T 3:1) for 5 hours at 37° C. with BD GolgiStop, FITC-conjugated anti-CD107a/b antibodies and 10 ug/mL blocking antibodies, or relevant isotype control.
  • Flow cytometry was performed to determine degranulation.
  • NK cells were defined as viable CD3-CD16dimCD56bright.
  • the bottom graph shows CD56bright NK cells from a single healthy donor co-cultured separately with RA-FLS from five different patients. * P ⁇ 0.05.
  • FIG. 5 A shows an LDH release assay that was employed to assess NK cell-mediated cytotoxicity of FLS using two different NK cell lines (NKL, left; and Nishi, right) in the presence of NNC141-0100 (HumZ270, black bars), isotype control (white bars), or medium alone (gray bars).
  • the NK cell effector to target ratio was 1:1.
  • FIG. 5 B shows that blocking NKG2A using NNC141-0100 (humZ270) leads to increased lysis of a representative RA-FLS (RA-FLS2, left panel) but does not affect elimination of a normal foreskin fibroblast cell line (FSK4, right panel).
  • Example 6 Treatment with humZ270 (Anti-NKG2A) Inhibits Formation of TRAP+ Multinucleated Osteoclasts
  • FIG. 6 A shows a representative example where 10 6 SFMC/well derived from a RA patient were cultured for 7 days in medium supplemented with 10 ng/mL IL-15. Cultures were treated with 20 microgram/ml human IgG4 isotype control ( FIG. 6 A .) or 20 microgram/ml humZ270 ( FIG. 6 B .) at the beginning of the assay. It can be appreciated that anti-NKG2A treatment in FIG. 6 B results in significant elimination of large plastic adherent multinucleated cells that express TRAP (i.e. defined as osteoclasts).
  • TRAP i.e. defined as osteoclasts
  • 20 microgram/mL human IgG4 isotype white and dark gray bars
  • 20 microgram/mL NNC141-0100 humZ270, light gray and black bars
  • Osteoclasts were quantitated as numbers of TRAP+ multinuclear cells/well.
  • FIG. 6 D a representative example of bone mineral erosion observed from an SFMC culture of RA patient no. 2357 is shown.
  • SFMC were grown on discs coated with a thin layer of bone mineral substrate (i.e. osteologic discs) in the presence of IL-15 and isotype mAb (left) vs anti-NKG2A (humZ270, right).
  • the discs were subsequently stained with von Kossa and eroded areas were analyzed using Immunospot S5 Analyzer and appear as light/white areas against the darker background.
  • FIG. 6 E data obtained from in total 5 RA patients is demonstrated.
  • SFMC were cultured in medium supplemented with 10 ng/mL IL-15.
  • 20 microgram/mL human IgG4 isotype (white bar) or 20 microgram/mL NNC141-0100 (humX270, black bar) were added to the cultures.
  • the mean percentage+/ ⁇ SEM eroded disc area was quantitated using Immunospot S5 Analyzer.
  • FIG. 6 D and FIG. 6 E show that anti-NKG2A treatment results in a significant reduction in the formation of active bone mineral eroding osteoclasts.
  • the findings suggest that therapeutic treatment in RA patients with anti-NKG2A mAb would result in dampening of bone erosion, a major clinical hallmark of RA.
  • FIG. 6 F illustrates that HumZ270 (anti-NKG2A) suppresses bone erosion in RA synovial tissue explant cultures cultured directly ex vivo.
  • RA synovial tissue shavings were grown for 7 days in IMDM medium supplemented with 10% FBS, 2% HuS, P/S, L-glut without addition of mAbs (control) or with addition of isotype, infliximab (IFX), or anti-NKG2A (humZ270), all mAbs at 10 micrograms/mL added in the beginning of the culture.
  • the experiment was set up in triplicate wells. At day 7, the medium and cells were removed by rinsing the wells 3 ⁇ with 200 uL MILLIi-Q water.
  • the discs were subsequently rinsed with 200 uL bleach solution ( ⁇ 6% NaOCl, ⁇ 5.2% NaCl) for 5 minutes followed by gentle pipetting to dislodge any remaining cells. Finally, the discs were washed 3 ⁇ with MILLI-Q water, air-dried and stained with the von Kossa method. It can be appreciated from this example of triplicate cultures that humZ270 treatment of RA synovial tissue explants results in decreased erosion (light/white areas) as compared to control or isotype treated cultures.
  • FIG. 6 G the calculated results (mean+/ ⁇ SEM) from triplicate cultures of RA synovial tissue shavings that have been grown for 7 days in IMDM medium supplemented with 10% FBS, 2% HuS, P/S, L-glut without addition of mAbs (control) or with addition of isotype, infliximab (IFX), or anti-NKG2A (humZ270), all mAbs at 10 micrograms/mL added in the beginning of the culture, are illustrated.
  • the medium and cells were removed by rinsing the wells 3 ⁇ with 200 uL MILLI-Q water.
  • RA synovial tissue explants were subsequently rinsed with 200 uL bleach solution ( ⁇ 6% NaOCl, ⁇ 5.2% NaCl) for 5 minutes followed by gentle pipetting to dislodge any remaining cells. Finally, the discs were washed 3 ⁇ with MILLI-Q water, air-dried and stained with the von Kossa method.
  • RA tissue growing directly ex vivo on discs coated with bone minerals i.e. osteologic discs
  • show significant erosive capacity and such activity is drastically inhibited by treatment with anti-NKG2A, clearly suggesting that therapeutic treatment in RA patients with anti-NKG2A would suppress bone erosion, a major clinical hallmark of RA.
  • Example 7 Modulation of Cytokine Levels in SFMC In Vitro Cultures Upon Treatment with HumZ270 (NNC141-0100)
  • SFMC were cultured for 7 days in medium supplemented with 10 ng/mL IL-15. Cultures were treated with 20 micrograms/mL human IgG4 isotype (light gray bars) or 20 micrograms/mL NNC141-0100 (humZ270, dark gray bars) at the beginning of the assay. Supernatant was harvested at 24 hours and the levels of cytokines were measured by BioPlex. The IL-6 levels are significantly reduced upon treatment with anti-NKG2A, while the production of other cytokines is not significantly affected, except for a small increase in M-CSF at 24 hours.
  • FIG. 7 B shows a pairwise comparison between the IL-6 levels measured in RA-SFMC in vitro cultures stimulated with IL-15 and treated with isotype vs HumZ270 (anti-NKG2A).
  • the IL-6 levels are significantly reduced upon masking NKG2A in all SFMC in vitro cultures.
  • NNC141-0100 inhibits both baseline and IL-15 stimulated IL-6 production in in vitro cultures of SFMC derived from patients with RA.
  • IL-6 levels produced by SFMC derived from 2 patients with RA were measured in cultures established in medium alone or medium supplemented with 10 ng/mL IL-15 as indicated. Cultures were treated with 20 micrograms/mL human IgG4 isotype (black bars) or 20 micrograms/mL NNC141-0100 (humZ270, white bars) at the beginning of the assay. Supernatant was harvested at 24, 48 and 72 hours and the levels of IL-6 were measured by BioPlex. Taken together, FIGS.
  • IL-6 is an important pro-inflammatory cytokine involved in the RA pathogenesis. Potentially, the reduction in IL-6 plays a role in the observed reduction in osteoclast formation.
  • Example 8 NKG2A and/or its Ligand HLA-E is Expressed in Inflamed Synovium from RA, Osteoarthritis (OA) and Psoriatic Arthritis (PsA) Patients
  • NK cells present in RA synovial tissue express the inhibitory NKG2A receptor and are localized predominantly in lymphoid aggregates adjacent to synoviocytes that express HLA-E, the ligand for CD94-NKG2A. This is shown in FIG. 8 . where representative pictures of RA synovial tissue from two out of 15 donors are depicted (ID 1144-09: A, C, E, G, I and ID 1591-08: B, D, F, H, J). Serial sections of RA synovium were stained for NK cells with an anti-NKp46 antibody ( FIGS. 8 A . and 8 B.), for NKG2A with the Z199 antibody ( FIGS. 8 C .
  • NK cells can be identified among the infiltrating lymphocyte population in the synovium of RA patients, and suggest that most, if not all, NK cells express NKG2A.
  • the ligand for CD94-NKG2A, HLA-E is expressed by many infiltrating immune cells, vascular endothelial cells and synoviocytes (macrophage-like synoviocytes (MLS) and RA-FLS).
  • MLS macrophage-like synoviocytes
  • RA-FLS RA-FLS
  • Subsets of NKG2A+NK cells are found in areas close to HLA-E + synoviocytes. Thus, this could potentially mean that NKG2A+NK cells recognize HLA-E on RA-FLS in situ.
  • HLA-E + infiltrating immune cells and vascular endothelium may also be recognized by NKG2A* NK cells.
  • NKG2A and its ligand, HLA-E are expressed in synovium of patients with osteoarthritis (OA). This is shown in FIG. 9 ., which depicts NKG2A* cells (Z199 antibody) among infiltrating lymphocytes ( FIG. 9 A .) and HLA-E expression (3D12 antibody) by infiltrating immune cells, endothelial cells and synoviocytes ( FIG. 9 B .).
  • NKG2A+ cells were present in the synovium of 6/9 OA patients.
  • NKG2A+NK cells may recognize HLA-E + synoviocytes, vascular endothelium and infiltrating immune cells in inflamed synovium of OA patients.
  • the ligand for CD94-NKG2A, HLA-E was found to be expressed in inflamed synovium from not only RA and OA, but also psoriatic arthritis (PsA) patients. This is shown in FIG. 10 . which depicts staining of synovial tissue samples from RA, OA and PsA patients (as indicated) with the anti-HLA-E antibody mAb MEM-E/02. In synovium of normal controls, HLA-E expression is observed in vascular endothelium and, more weakly, in subsets of synoviocytes located in the synovial lining, as indicated in FIG. 10 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-NKG2A antibody.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of U.S. application Ser. No. 16/718,935, filed Dec. 18, 2019, now allowed, which is a continuation of U.S. application Ser. No. 15/355,087, filed Nov. 18, 2016, now abandoned, which is a continuation of U.S. application Ser. No. 14/124,876, filed Feb. 24, 2014, now U.S. Pat. No. 9,512,228, which is a 35 U.S.C. § 371 National Stage application of International Application PCT/EP2012/061583 (WO 2012/172102 A1), filed Jun. 18, 2012, which claimed priority of European Patent Application 11170402.9, filed Jun. 17, 2011; this application claims priority under 35 U.S.C. § 119 of U.S. Provisional Application 61/501,533; filed Jun. 27, 2011.
    • TECHNICAL FIELD
  • The present invention relates to treatment of bone erosion and cartilage destruction, in particular treatment of bone and cartilage destroying diseases using biological drugs such as antibodies.
  • In accordance with 37 C.F.R. § 1.52(e)(5), Applicants enclose herewith the Sequence Listing for the above-captioned application entitled “Seq-List.xml”, created on May 21, 2023. The Sequence Listing is made up of 7,507 bytes, and the information contained in the attached “Seq-List.xml” is identical to the information in the specification as originally filed. No new matter is added.
    • BACKGROUND
  • Natural killer (NK) cells are bone marrow derived lymphocytes essential for host defense against certain infections and tumors. Upon activation they rapidly produce a range of cytokines and can mediate cytotoxic responses against infected, stressed, or tumorigenic cells. The role of NK cells in chronic inflammatory diseases is emerging, and it is becoming increasingly appreciated that NK cells may play an important role in the modulation of T and B cell responses through their capacity to promote differentiation and maturation of dendritic cells (DC) and subsequent polarization of T cell responses (see, e.g., Cooper et al. (2004) Trends Immunol. 25: 47-52; Zhang et al. (2007) Blood Oct 1;110(7):2484-93). Furthermore, studies have shown that NK cells have the capacity to directly eliminate subsets of activated T cells via cell-mediated cytotoxic responses (Lu et al. (2007) Immunity. 26: 593-604). NK cell activity is regulated by a complex mechanism that involves both activating and inhibitory signals (see, e.g., Moretta et al. (2001) Annu Rev Immunol 19:197-223; Moretta et al. (2003) EMBO J EPub December 18; Ravetch et al. (2000) Science 290:84-89; Zambello et al. (2003) Blood 102:1797-805; Moretta et al. (1997) Curr Opin Immunol 9:694-701.
  • Several different NK-specific receptors have been identified that are involved in NK cell mediated recognition and killing of HLA Class I deficient target cells. One import inhibitory NK cell receptor is CD94/NKG2A, which interacts with the non-classical MHC class I molecule HLA-E (see, e.g., Braud et al. (1998) Nature 391:795-799; Lee et al. (1998) PNAS 95:5199-5204; Vance et al. (2002) PNAS 99:868-873; Brooks et al. (199) J Immunol 162:305-313; Miller et al. (2003) J Immunol 171:1369-75; Brooks et al. (1997) J Exp Med 185:795-800; Van Beneden et al. (2001) 4302-4311; US Patent application no. 20030095965).
  • CD94/NKG2A is an inhibitory receptor found on subsets of NK, NKT and T cells, which restricts their killing of cells expressing the CD94/NKG2A-ligand HLA-E carrying small peptides typically derived from the leader sequence of other MHC class I molecules (see, e.g., WO99/28748 and Braud et al. (1998) Nature 391:795-799).
  • Various antibodies against NKG2A have been described in the art. For example Sivori et al. (Eur J Immunol 1996; 26:2487) refers to the murine anti-NKG2A antibody Z270; Carretero et al. (J Exp Med 1999; 190:1801-12) refers to rat anti-murine NKG2A antibody 20D5; US patent application 20030095965 describes murine antibody 3S9, which binds to NKG2A, NKG2C and NKG2E; patent application WO06070286 discloses monoclonal antibodies against NKG2A; and patent application WO2008/009545 describes the humanized antibody humZ270 and other anti-NKG2A antibodies with substantially identical variable heavy chain and/or variable light chain to those of Z270.
    • SUMMARY
  • Rheumatoid arthritis (RA) is a chronic inflammatory disease where activation of inflammatory mediators produced by multiple cellular subsets eventually results in destruction of joint cartilage and bone. It is generally accepted that the main cellular subsets responsible for cartilage and bone destruction in RA are fibroblast-like synoviocytes (FLS) and osteoclasts, respectively. CD94-NKG2A expressing T cells and NK cells can suppress inflammation by killing activated proinflammatory cells. Activation of these cells can be accomplished by a series of different cells and molecules including macrophages, activated CD4+ T cells and B cells/plasma cells. However, this regulatory, anti-inflammatory activity is inhibited when CD94-NKG2A receptors engage their HLA-E ligand at the surface of pro-inflammatory cells. By blocking CD94-NKG2A receptors and preventing their inhibitory signalling, NNC141-0100 enhances anti-inflammatory activities of regulatory CD94-NKG2A+T cells and NK cells, boosting their ability to eliminate e.g. activated pro-inflammatory CD4+ T cells and fibroblast-like synoviocytes (FLS). A therapy that specifically eliminates aggressive cartilage-eroding FLS and suppresses the formation of bone erosive osteoclasts while leaving resting cells unaffected may have a significant advantage over current RA therapies and could potentially also, with benefit for the patients, be used in treating osteoarthritis (OA) and psoriatic arthritis (PsA).
  • This invention discloses how an anti-NKG2A antibody attenuates two major pathogenic pathways in RA, i.e. bone and cartilage erosion, by its capacity to reduce formation of bone-degrading osteoclasts and by selectively enhancing elimination of cartilage-degrading FLS, respectively.
  • Existing therapeutics targeting RA act directly on individual components of the inflammatory cascade, and their efficacy with regard to bone erosion is secondary to their anti-inflammatory effect. Anti-NKG2A mAbs capable of inhibiting binding of HLA-E or which can non-competitively block the function of CD94/NKG2A and stimulate the endogenous immune-regulatory mechanism of NK cells result in selective elimination of cells that promote cartilage degradation, bone erosion and reduction in IL-6, a cytokine known to promote inflammation. Thus, therapeutic treatment with an anti-NKG2A mAb can have a direct effect on the pathogenesis in diseases characterized by bone erosion or cartilage destruction.
  • The present invention discloses the use of an anti-NKG2A antibody, or a fragment thereof, capable of treating cartilage destruction and/or bone erosion.
  • The present invention discloses the use of an anti-NKG2A antibody for the treatment of a disease or disorder characterized by cartilage destruction and/or bone erosion.
  • The present invention discloses the use of an anti-NKG2A antibody for the treatment of cartilage destruction and/or bone erosion wherein the anti-NKG2A antibody stimulates selective elimination of activated cells that promote cartilage degradation or bone erosion. In one embodiment of the current invention the cartilage-degrading cells are fibroblast-like synoviocytes (FLS). In one embodiment the bone-eroding cells are erosive osteoclasts.
  • The present invention discloses the use of an anti-NKG2A antibody for the treatment of a disease or disorder characterized by cartilage destruction and/or bone erosion, wherein the anti-NKG2A antibody stimulates selective elimination of activated cells that promote cartilage degradation or bone erosion. In one embodiment of the current invention the cartilage-degrading cells are fibroblast-like synoviocytes (FLS). In one embodiment the bone-eroding cells are erosive osteoclasts.
  • The NKG2A antibodies used in the current invention can be any suitable anti-NKG2A antibodies. In one embodiment, the antibody is a monoclonal anti-NKG2A antibody. In one embodiment, the antibody is a humanized anti-NKG2A antibody. In one embodiment, the antibody is a fully human anti-NKG2A antibody. In one embodiment, the antibody is an anti-NKG2A antibody as described in WO2008/009545. In one embodiment, the anti-NKG2A monoclonal antibody is humZ270 as described in patent publication WO2008/009545. In one embodiment, the anti-NKG2A antibody is a monoclonal anti-NKG2A antibody as described in patent publication WO09092805. In one embodiment, the anti-NKG2A antibody is humZ199 as described in patent publication WO09092805.
    • BRIEF DESCRIPTION OF DRAWINGS
  • FIGS. 1A.-1E. illustrate the expression profile of a panel of cell surface molecules expressed by in vitro generated fibroblast-like synoviocytes derived from the synovial tissue of patients with rheumatoid arthritis (RA).
      • FIG. 1A. shows that fibroblast-like synoviocytes (FLS) derived from RA patients express CD55 (right histogram overlay) but lack CD68 (left histogram overlay).
      • FIG. 1B. shows that RA-FLS cell surfaces express several ligands for activating NK cell receptors (e.g. MICA, ULBP1, ULBP2, ULBP3, ICAM1, CD155, CD48) as indicated below each histogram overlay. As indicated RA-FLS stain effectively with NKp44-FC fusion suggesting that RA-FLS express a putative ligand for NKp44.
      • FIG. 1C. shows that an antibody against NKp44 dose-dependently prevents binding of a soluble NKp44-FC fusion protein on RA-FLS suggesting that RA-FLS express a ligand capable of interacting with NKp44 receptors.
      • FIG. 1D. shows that RA-FLS express MHC class I ligands HLA-E and HLA-G, ligands known to be recognized by NK cell receptors (e.g. CD94/NKG2A and LIR-1, respectively).
      • FIG. 1E. shows that RA-FLS express death receptor 5 (DR5) but not DR4, known receptors that bind TRAIL.
  • FIGS. 2A.-2H. show that NKG2A expressing NK cells are present in RA synovium and can be found in areas containing HLA-E expressing RA-FLS.
      • FIG. 2A. shows RA synovial tissue stained with an antibody against human NKp46. The dark stained areas are NKp46 expressing cells.
      • FIG. 2B. shows an adjacent section of the same tissue stained with an antibody against human NKG2A. The dark stained areas are NKG2A expressing cells.
      • FIG. 2C. shows an adjacent tissue section stained with an isotope control antibody.
      • FIG. 2D. shows the frequency of NKG2A+ cells/mm2 synovial tissue plotted against the frequency of NKp46+ cells/mm2 synovial tissue as evaluated by quantitative digital image analysis. The data indicate that most NKG2A+ cells are NK cells in the inflamed RA synovial tissue.
      • FIG. 2E. shows RA synovial tissue stained with anti-HLA-E antibody. Cells in the synovial lining, including RA-FLS, express HLA-E. The arrow indicates an area of darkly stained HLA-E expressing synovial lining FLS-like cells.
      • FIG. 2F. shows that infiltrating immune cells in the synovial sublining express HLA-E.
      • FIG. 2G. shows RA synovial tissue stained with isotype control antibody.
      • FIG. 2H. shows that vascular endothelial cells express HLA-E.
  • FIGS. 3A.-3D. show that NK cells, including synovial NK cells derived from RA patients, express a panel of activating receptors known to bind to ligands that are expressed on RA-FLS.
      • FIGS. 3A.(i)-(iii):
        • FIG. 3A. (i) shows NK cell receptor expression on gated NK cells derived from SFMC of a representative RA patient. Synovial NK cells express NKG2D, NKp30, NKp44, NKp46, DNAM1, 2B4, LFA-1, and TRAIL, but no, or very low levels of NKG2C as indicated by the open histogram overlays.
        • FIG. 3A. (ii) shows resting CD56bright NK cells from PBMC derived from a representative healthy donor. CD56bright NK cells express NKG2D, NKp30, NKp44, NKp46, DNAM1, 2B4, LFA-1, and TRAIL, but no, or very low levels of NKG2C as indicated by the open histogram overlays.
        • FIG. 3A. (iii) shows Nishi NK cells. Nishi NK cells express NKG2D, NKp30, NKp44, NKp46, DNAM1, 2B4, LFA-1, and TRAIL, but no, or very low levels of NKG2C as indicated by the open histogram overlays.
      • FIGS. 3B.(i)-(ii) show that NK cells eliminate adherent RA-FLS in vitro:
        • FIG. 3B. (i) shows that NK cells co-cultured with RA-FLS overnight results in the elimination of adherent RA-FLS in a dose dependent manner.
        • FIG. 3B (ii). shows the well area covered by adherent RA-FLS when cultured alone, or when co-cultured with decreasing amounts of NK cells overnight, as analyzed by Immunospot image analysis.
      • FIG. 3C. shows that NK cells degranulate as measured by CD107a/b cell-surface expression when co-cultured with RA-FLS, but not when cultured alone, indicating that NK cells actively kill RA-FLS.
      • FIG. 3D shows that masking NKG2D, NKp44, NKp46, DNAM-1, or TRAIL expressed by NK cells results in significantly reduced killing of RA-FLS as measured by CD107a/b cell surface expression on effector NK cells.
  • FIGS. 4A.-4E. show that RA-FLS are protected from NK cell-mediated cytotoxicity by expression of HLA-E capable of ligating to inhibitory CD94-NKG2A NK cell receptors.
      • FIG. 4A. shows that RA synovial NK cells (top panel), CD56bright healthy PB-NK cells (middle panel), and Nishi NK cells (bottom panel) all express cell surface NKG2A (left), but lack KIRs (right). In addition, Nishi cells, but not synovial NK cells or CD56bright NK cells, express LIR1 (middle panel).
      • FIG. 4B. shows increased NK cell degranulation as measured by CD107a/b cell-surface expression when NK cells are co-cultured with RA-FLS in the presence of anti-NKG2A (right panel), but not in the presence of anti-LIR1 (left panel).
      • FIG. 4C. shows increased NK cell-dependent clearance of adherent RA-FLS when treated with anti-NKG2A (right image) as compared to treatment with an isotype control (middle image). RA-FLS cultured in the absence of NK cells is shown in the left micrograph image.
      • FIG. 4D. shows that synovial NK cells degranulate when co-cultured with autologous RA-FLS (14%, top left) and that masking NKG2A results in increased degranulation (44%, top right). Autologous CD3+CD8+ T cells do not significantly degranulate when co-cultured with autologous RA-FLS in the absence (i.e. isotype treated cultures, bottom left) or presence (bottom right) of anti-NKG2A.
      • FIG. 4E. shows that freshly isolated and unstimulated CD56bright PB-NK cells from healthy donors degranulate when cocultured with RA-FLS in the presence of anti-NKG2A but minimally so when treated with an isotype control antibody. The top panel shows a representative example and the bottom graph shows the % CD107a/b expression on 5 separate donor CD56bright NK cells co-cultured with RA-FLS in the presence of an isotype vs anti-NKG2A.
  • FIG. 5A. shows that blocking NKG2A using NNC141-0100 (humZ270) leads to increased NK cell-mediated elimination of RA-FLS as measured by an LDH release assay. NKL effector cells are shown on the left and Nishi NK cells on the right against a representative RA-FLS target cell.
  • FIG. 5B. shows that blocking NKG2A using NNC141-0100 (humZ270) leads to increased lysis of a representative RA-FLS (RA-FLS2) but does not affect elimination of a normal foreskin fibroblast cell line (FSK4).
  • FIGS. 6A.-6G. show that NNC141-0100 (humZ270) inhibits formation of TRAP+ multinucleated osteoclasts:
      • FIG. 6A. shows a representative example of RA-SFMC cultured for 7 days in the presence of humIgG4 isotype. Several large multinucleated TRAP+ cells are visible.
      • FIG. 6B. shows that humZ270 treatment results in drastically reduced numbers of large multinucleated TRAP+ cells.
      • FIG. 6C. shows formation of osteoclasts in SFMC derived from patients with RA cultured in medium or IL-15 in the presence of an isotype control vs anti-NKG2A (humZ270, NNC141-0100) as indicated. Masking NKG2A in cultures stimulated with IL-15 results in reduced number of TRAP+ multinucleated cells.
      • FIG. 6D. shows that formation of bone-mineral eroding osteoclasts in SFMC derived from patients with RA is suppressed by treatment with NNC141-0100. Shown is a representative example of bone mineral erosion observed from an SFMC culture of RA patient no. 2357. SFMC were grown on osteologic discs in the presence of IL-15 and isotype mAb (left) vs anti-NKG2A (humZ270, right). The discs were stained with von Kossa and eroded areas were analyzed using Immunospot S5 Analyzer and appear white against the darker background.
      • FIG. 6E. SFMC derived from RA patients (n=5) were cultured in medium supplemented with 10 ng/mL IL-15. At the beginning of the assay, 20 microgram/mL human IgG4 isotype (white bar) or 20 microgram/mL NNC141-0100 (humZ270,black bar) were added to the cultures. The mean percentage+/−SEM eroded disc area was quantitated using Immunospot S5 Analyzer.
      • FIG. 6F shows that HumZ270 suppresses bone mineral erosion in RA synovial tissue explant cultures. The figure shows an example where RA synovial tissue shavings were grown in triplicate wells on bone mineral discs in the presence of medium alone (control, top), isotype control (second from top), infliximab (IFX, third from top), or anti-NKG2A (humZ270, bottom). The light areas represent bone mineral erosion.
      • FIG. 6G. shows percentage bone mineral erosion observed as determined by analysis using an Immunospot analyzer.
  • FIG. 7A. shows modulation of cytokine levels as measured at 24 hrs in SFMC in vitro cultures upon treatment with humZ270 (NNC141-0100, dark gray bars) as compared to an isotype control (light gray bars). A significant reduction in IL6 levels is observed upon masking NKG2A. In addition, a slight increase in M-CSF is observed.
  • FIG. 7B. shows a pairwise comparison of IL-6 levels produced in the presence of anti-NKG2A (NNC141-0100, humZ270) vs isotype control in RA-SFMC cultures (n=11).
  • FIG. 7C. shows that anti-NKG2A inhibits both baseline (i.e. medium alone) and IL-15 stimulated IL-6 production in ex vivo cultures of SFMC derived from patients with RA. Mean and SD of two representative RA patients are shown.
  • FIGS. 8A.-8M. show that NK cells present in RA synovial tissue express the inhibitory NKG2A receptor and are localized predominantly in lymphoid aggregates adjacent to synoviocytes that express HLA-E, the ligand for CD94-NKG2A.
      • 8A. shows RA synovial tissue from ID 1144-09 stained for NK cells with an anti-NKp46 antibody.
      • 8B. shows RA synovial tissue from ID 1591-08 stained for NK cells with an anti-NKp46 antibody.
      • 8C. shows RA synovial tissue from ID 1144-09, stained for NKG2A with the Z199 antibody (an anti-NKG2A antibody).
      • 8D. shows RA synovial tissue from ID 1591-08, stained for NKG2A with the Z199 antibody (an anti-NKG2A antibody).
      • 8E. shows RA synovial tissue from ID 1144-09, stained for HLA-E with the 3D12 antibody.
      • 8F. shows RA synovial tissue from ID 1591-08, stained for HLA-E with the 3D12 antibody.
      • 8G. shows RA synovial tissue from ID 1144-09, stained for T cells with an anti-CD3 antibody.
      • 8H. shows RA synovial tissue from ID 1591-08, stained for T cells with an anti-CD3 antibody.
      • 8I. shows RA synovial tissue from ID 1144-09, stained with an IgG2b isotype control antibody.
      • 8J. shows RA synovial tissue from ID 1591-08, stained with an IgG2b isotype control antibody.
      • 8K. shows a high magnification picture of NKp46+NK cells from ID 1595-08.
      • 8L. shows a high magnification picture of NKG2A+ cells from ID 1595-08.
      • 8M. shows a digital image analysis for correlation of the number of NKG2A+ cells in synovium from 15 RA patients with the number of NKp46+NK cells.
  • FIGS. 9A.-9C. show that NKG2A and its ligand, HLA-E, are expressed in synovium of patients with osteoarthritis (OA).
      • 9A. depicts NKG2A* cells (Z199 antibody) among infiltrating lymphocytes.
      • 9B. depicts HLA-E expression (3D12 antibody) by infiltrating immune cells, endothelial cells and synoviocytes.
      • 9C. shows a digital image analysis for correlation of the frequency of NKG2A+ cells with that of NK cells in OA synovium.
  • FIGS. 10A.-10D. show that the CD94-NKG2A ligand was found to be expressed in inflamed synovium from not only RA and OA patients, but also PsA patients.
      • 10A. depicts staining of synovial tissue samples from RA patient.
      • 10B. depicts staining of synovial tissue samples from PsA patient.
      • 10C. depicts staining of synovial tissue samples from RO (OA????) patient.
      • 10D. depicts staining of synovial tissue samples from normal control.
  • FIGS. 11A.-11E. show the amino acid sequence of:
      • 11A.: SEQ. ID. NO. 1, humNKG2A.
      • 11B.: SEQ. ID. NO. 2, heavy chain variable domain (VH) of the humZ270 antibody.
      • 11C.: SEQ. ID. NO. 3, light chain variable domain (VL) of the humZ270 antibody.
      • 11D.; SEQ. ID. NO. 4, heavy chain variable domain (VH) of the humZ199 antibody.
      • 11E. SEQ. ID. NO. 5, light chain variable domain (VL) of the humZ199 antibody.
     DESCRIPTION
  • The term “antibody” as referred to herein refers to a polypeptide derived from a germline immunoglobulin sequence. The term includes full-length antibodies and any antigen binding fragments or single chains thereof. The terms “antibody”, “monoclonal antibody” and “mAb”, as used herein, are intended to refer to immunoglobulin molecules and fragments thereof that have the ability to specifically bind to an antigen. A sub-class of the immunoglobulins of particular pharmaceutical interest are those belonging to the IgG family, which can be subdivided into the iso-types IgG1, IgG2, IgG3 and IgG4. IgG molecules are composed of two heavy chains interlinked by two or several disulfide bonds and two light chains, one attached to each of the heavy chains by a disulfide bond. The IgG heavy chain is composed of four Ig-domains, including the variable domain (VH) and three constant domains (CH1, CH2, and CH3). Each light chain is comprised of a light chain variable region (VL) and a light chain constant region (CL). The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
  • The constant regions of the antibodies may mediate the binding of the antibody to host tissues or factors, including various cells of the immune system (e.g., effector cells), Fc receptors (FcRs) and the first component (C1q) of the classical complement system. Binding to FcRs and C1q may mediate effects such as ADCC or CDC.
  • An antibody of the invention may be any NKG2A binding antibody, the humZ270 antibody (SEQ. ID. NO. 2 and SEQ. ID. NO. 3) or the humZ199 antibody (SEQ. ID. NO. 4 and SEQ. ID. NO. 5) or any other antibody of the invention, or a variant of any one of these antibodies.
  • The term humanized Z270 or humZ270 or hZ270, as used herein, comprises the antibody disclosed in the patent application WO08009545, which is hereby incorporated by reference into this application. The term humanized Z199 or humZ199 as used herein, comprises the antibody disclosed in the patent publication WO09092805, which is hereby incorporated by reference into this application.
  • As used herein, the term Ab comprises an antibody, or a fragment thereof, which specifically binds its corresponding Ag. Examples of antigen-binding fragments include, but are not restricted to, Fab, Fab′, F(ab)2, F(ab′)2, Fv (typically the VL and VH domains of a single arm of an antibody), single-chain Fv (scFv; see, e.g., Bird et al., Science 1988; 242:425-426; and Huston et al. PNAS 1988; 85:5879-5883), dsFv, Fd (typically the VH and CHI domain), and dAb (typically a VH domain) fragments; VH, VL, VhH, and V-NAR domains; monovalent molecules comprising a single VH and a single VL chain; minibodies, diabodies, triabodies, tetrabodies, and kappa bodies (see, e.g., Ill et al., Protein Eng 1997; 10:949-57); camel IgG; IgNAR; and one or more isolated CDRs or a functional paratope, where the isolated CDRs or antigen-binding residues or polypeptides can be associated or linked together so as to form a functional antibody fragment. Various types of antibody fragments have been described or reviewed in, e.g., Holliger and Hudson, Nat Biotechnol 2005;2S:1126-1136; WO2005040219; and published U.S. Patent Applications 20050238646 and 20020161201.
  • The term “antigen-binding fragment” of an antibody refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen, such as NKG2A or another target molecule as described herein. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments encompassed within the term “antigen-binding fragment” of an antibody include a Fab fragment, a F(ab′)2 fragment, a Fab′ fragment, a Fd fragment, a Fv fragment, a ScFv fragment, a dAb fragment and an isolated complementarity determining region (CDR). Single chain antibodies such as scFv and heavy chain antibodies such as VHH and single domain camel antibodies are also intended to be encompassed within the term “antigen-binding portion” of an antibody. These antibody fragments may be obtained using conventional techniques known to those of skill in the art, and the fragments may be screened for utility in the same manner as intact antibodies.
  • A “Fab” fragment includes a variable domain and a constant domain of the light chain and a variable domain and the first constant domain (CH1) of the heavy chain. A Fab′ fragment includes one or more cysteine carboxy terminal linkages to the heavy or light chains. F(ab′)2 antibody fragments comprise a pair of Fab fragments that are generally covalently linked near their carboxy termini by hinge cysteines. Other chemical couplings of antibody fragments are also known in the art. A Fab fragment retains the ability of the parent antibody to bind to its antigen, potentially with a lower affinity. F(ab′)2 fragments are capable of divalent binding, whereas Fab fragments can bind monovalently only. Generally, Fab fragments lack the constant CH2 and CH3 domains, i.e. the Fc part, where interaction with the Fc receptors would occur. Thus, Fab fragments are in general devoid of effector functions.
  • An “Fv” fragment is an antibody fragment that contains a complete antigen recognition and binding site, and generally comprises a dimer of one heavy and one light chain variable domain in tight association that can be covalent in nature, for example in a single chain variable domain fragment (scFv). It is in this configuration that the three hypervariable regions of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer. Collectively, the six hypervariable regions or a subset thereof confer antigen binding specificity to the antibody. However, even a single variable domain comprising only three hypervariable regions specific for an antigen has the ability to recognize and bind the antigen, although usually at a lower affinity than the entire binding site (Cai & Garen, Proc. Natl. Acad. Sci. USA, 93: 6280-6285, 1996). For example, naturally occurring camelid antibodies that only have a heavy chain variable domain (VHH) can bind antigens (Desmyter et al., J. Biol. Chem., 277: 23645-23650, 2002; Bond et al., J. Mol. Biol. 2003; 332: 643-655).
  • “Single-chain Fv” or “scFv” antibody fragments comprise the VH and VL domains of the antibody, where these domains are present in a single polypeptide chain. Generally, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains that enables the scFv to form the desired structure for antigen binding. For a review of scFv, see Pluckthun, 1994, in The Pharmacology of Monoclonal Antibodies, Vol. 113, Rosenburg and Moore eds. Springer-Verlag, New York, pp. 269-315.
  • The term “diabodies” refers to small antibody fragments with two antigen-binding sites, in which fragments comprise a heavy chain variable domain (VH) connected to a light chain variable domain (VL) in the same polypeptide chain (VH and VL). By using a linker that is too short to allow pairing between the two variable domains on the same chain, the variable domains are forced to pair with complementary domains of another chain, creating two antigen-binding sites. Diabodies are described more fully, for example, in EP 404,097; WO 93/11161; and Hollinger et al., 1993, Proc. Natl. Acad. Sci. USA, 90:6444-6448.
  • The expression “linear antibodies” refers to antibodies as described in Zapata et al., 1995, Protein Eng., 8(10):1057-1062. Briefly, these antibodies contain a pair of tandem Fd segments (VH-CH1-VH-CH1) that, together with complementary light chain polypeptides, form a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific.
  • The term “monobody”, as used herein, refers to an antigen-binding molecule with a heavy chain variable domain and no light chain variable domain. A monobody can bind to an antigen in the absence of light chains and typically has three hypervariable regions, for example CDRs designated CDRH1, CDRH2, and CDRH3. A heavy chain IgG monobody has two heavy chain antigen-binding molecules connected by a disulfide bond. The heavy chain variable domain comprises one or more hypervariable regions, preferably a CDRH3 or HVL-H3 region.
  • The term “hypervariable region”, when used herein, refers to the amino acid residues of an antibody that are responsible for antigen binding. The hypervariable region comprises amino acid residues from a “complementarity-determining region” or “CDR” (defined by sequence as residues 24-34 (L1), 50-56 (L2) and 89-97 (L3) in the light chain variable domain and 31-35 (H1), 50-65 (H2) and 95-102 (H3) in the heavy chain variable domain; Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)) and/or those residues from a “hypervariable loop” (defined by structure and differing for each antibody; see, for example, Chothia and Lesk, 1987, J. Mol. Biol. 196:901-917). In one example, HVL residues can include 26-32 (L1), 50-52 (L2) and 91-96 (L3) in the light chain variable domain and 26-32 (H1), 53-55 (H2) and 96-101 (H3) in the heavy chain variable domain.
  • Antibody fragments may be obtained using conventional recombinant or protein engineering techniques, and the fragments can be screened for binding to NKG2A, or another function, in the same manner as intact antibodies.
  • Antibody fragments of the invention may be made by truncation, e.g. by removal of one or more amino acids from the N and/or C-terminal ends of a polypeptide. Fragments may also be generated by one or more internal deletions.
  • An antibody of the invention may be, or may comprise, a fragment of any anti-NKG2A antibody, the humZ270 antibody (SEQ. ID. NO. 2 and SEQ. ID. NO. 3) or the humZ199 antibody (SEQ. ID. NO. 4 and SEQ. ID. NO. 5) or any other antibody of the invention, or a variant of any one of these antibodies. An antibody of the invention may be, or may comprise, an antigen binding portion of one of these antibodies, or variants thereof. For example, the antibody of the invention may be a Fab fragment of one of these antibodies or variants thereof, or it may be a single chain antibody derived from one of these antibodies, or a variant thereof.
  • An antibody of the invention may be a human antibody or a humanised antibody. The term “human antibody”, as used herein, is intended to include antibodies having variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences. Furthermore, if the antibody contains a constant region, the constant region is also derived from human germline immunoglobulin sequences. The human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). On the other hand, the term “human antibody”, as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.
  • Such a human antibody may be a human monoclonal antibody. Such a human monoclonal antibody may be produced by a hybridoma which includes a B cell obtained from a transgenic nonhuman animal, e.g., a transgenic mouse, having a genome comprising a human heavy chain transgene and a light chain transgene fused to an immortalized cell.
  • Human antibodies may be isolated from sequence libraries built on selections of human germline sequences, further diversified with natural and synthetic sequence diversity.
  • Human antibodies may be prepared by in vitro immunisation of human lymphocytes followed by transformation of the lymphocytes with Epstein-Barr virus.
  • The term “human antibody derivatives” refers to any modified form of the human antibody, such as a conjugate of the antibody and another agent or antibody.
  • The term “humanized antibody”, as used herein, refers to a human/non-human chimeric antibody that contains a minimal sequence (CDR regions) derived from a non-human immunoglobulin. A humanized antibody is, thus, a human immunoglobulin (recipient antibody) in which residues from a hyper-variable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as from a mouse, rat, rabbit, or non-human primate, which have the desired specificity, affinity, and capacity. In some instances, FR residues of the human immunoglobulin are replaced by corresponding non-human residues. An example of such a modification is the introduction of one or more so-called back-mutations.
  • Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR residues are those of a human immunoglobulin sequence. The humanized antibody can optionally also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
  • The term “chimeric antibody”, as used herein, refers to an antibody whose light and heavy chain genes have been constructed, typically by genetic engineering, from immunoglobulin variable and constant region genes that originate from different species. For example, the variable segments of genes from a mouse monoclonal antibody may be joined to human constant segments.
  • The fragment crystallisable region (“Fc region”/“Fc domain”) of an antibody is the “tail” region of an antibody comprising the constant CH2 and CH3 domains. The Fc domain may interact with cell surface receptors called Fc receptors, as well as some proteins of the complement system. The Fc region enables antibodies to activate the immune system. In one aspect of the invention, antibodies may be engineered to include modifications within the Fc region, typically to alter one or more of its functional properties, such as serum half-life, complement fixation, Fc-receptor binding, protein stability and/or antigen-dependent cellular cytotoxicity, or lack thereof. Furthermore, an antibody of the invention may be chemically modified (e.g., one or more chemical moieties can be attached to the antibody) or be modified to alter its glycosylation, again to alter one or more functional properties of the antibody. Preferably, a modified Fc domain comprises one or more, preferably all of the following mutations that will result in decreased affinity to certain Fc receptors (L234A, L235E, and G237A) and in reduced Clq-mediated complement fixation (A330S and P331S), respectively.
  • The isotype of an antibody of the invention may be IgG, such as IgG1, IgG2, or IgG4. If desired, the class of an antibody may be “switched” by known techniques. For example, an antibody that was originally produced as an IgM molecule may be class switched to an IgG antibody. Class switching techniques may also be used to convert one IgG subclass to another, for example: from IgG1 to IgG2 or IgG4; from IgG2 to IgG1 or IgG4; or from IgG4 to IgG1 or IgG2. Engineering of antibodies to generate constant region chimeric molecules, by combination of regions from different IgG subclasses, can also be performed.
  • The term “epitope”, as used herein, is defined in the context of a molecular interaction between an “antigen binding polypeptide”, such as an antibody (Ab), and its corresponding “antigen” (Ag). The term antigen (Ag) refers to the molecular entity used for immunization of an immunocompetent vertebrate to produce the antibody (Ab) that recognizes the Ag. Herein, Ag is termed more broadly and is generally intended to include target molecules that are specifically recognized by the Ab, thus including fragments or mimics of the molecule used in the immunization process for raising the Ab.
  • Generally, “epitope” refers to the area or region on an Ag to which an Ab specifically binds, i.e. the area or region in physical contact with the Ab. A protein epitope may comprise amino acid residues in the Ag that are directly involved in binding to an Ab (also called the immunodominant component of the epitope) and other amino acid residues, which are not directly involved in binding, such as amino acid residues of the Ag which are effectively blocked by the Ab (in other words, the amino acid residue is within the “solvent-excluded surface” and/or the “footprint” of the Ab). The term epitope herein includes both types of binding sites in any particular region of NKG2A that specifically binds to an anti-NKG2A antibody, or another NKG2A-specific agent according to the invention, unless otherwise stated (e.g., in some contexts the invention relates to antibodies that bind directly to particular amino acid residues). NKG2A may comprise a number of different epitopes, which may include, without limitation, (1) linear peptide epitopes, (2) conformational epitopes which consist of one or more non-contiguous amino acids located near each other in the mature NKG2A conformation; and (3) post-translational epitopes which consist, either in whole or part, of molecular structures covalently attached to NKG2A, such as carbohydrate groups.
  • The epitope for a given antibody (Ab)/antigen (Ag) pair can be defined and characterized at different levels of detail using a variety of experimental and computational epitope mapping methods. The experimental methods include mutagenesis, X-ray crystallography, Nuclear Magnetic Resonance (NMR) spectroscopy, Hydrogen deuterium eXchange Mass Spectrometry (HX-MS) and various competition binding methods; methods that are known in the art. As each method relies on a unique principle, the description of an epitope is intimately linked to the method by which it has been determined. Thus, depending on the epitope mapping method employed, the epitope for a given Ab/Ag pair will be defined differently.
  • At its most detailed level, the epitope for the interaction between the Ag and the Ab can be defined by the spatial coordinates defining the atomic contacts present in the Ag-Ab interaction, as well as information about their relative contributions to the binding thermodynamics. At a less detailed level, the epitope can be characterized by the spatial coordinates defining the atomic contacts between the Ag and Ab. At an even less detailed level the epitope can be characterized by the amino acid residues that it comprises as defined by a specific criterion such as the distance between atoms in the Ab and the Ag. At a further less detailed level the epitope can be characterized through function, e.g. by competition binding with other Abs. The epitope can also be defined more generically as comprising amino acid residues for which substitution by another amino acid will alter the characteristics of the interaction between the Ab and Ag.
  • In the context of an X-ray derived crystal structure defined by spatial coordinates of a complex between an Ab, e.g. a Fab fragment, and its Ag, the term epitope is herein, unless otherwise specified or contradicted by context, specifically defined as NKG2A residues characterized by having a heavy atom (i.e. a non-hydrogen atom) within a distance of 4 Å from a heavy atom in the Ab.
  • From the fact that descriptions and definitions of epitopes, dependent on the epitope mapping method used, are obtained at different levels of detail, it follows that comparison of epitopes for different Abs on the same Ag can similarly be conducted at different levels of detail.
  • Epitopes described on the amino acid level, e.g. determined from an X-ray structure, are said to be identical if they contain the same set of amino acid residues. Epitopes are said to overlap if at least one amino acid is shared by the epitopes. Epitopes are said to be separate (unique) if no amino acid residues are shared by the epitopes.
  • Epitopes characterized by competition binding are said to be overlapping if the binding of the corresponding Abs are mutually exclusive, i.e. binding of one Ab excludes simultaneous binding of the other Ab. The epitopes are said to be separate (unique) if the Ag is able to accommodate binding of both corresponding Abs simultaneously.
  • The definition of the term “paratope” is derived from the above definition of “epitope” by reversing the perspective. Thus, the term “paratope” refers to the area or region on the Ab to which an Ag specifically binds, i.e. with which it makes physical contact to the Ag.
  • In the context of an X-ray derived crystal structure, defined by spatial coordinates of a complex between an Ab, such as a Fab fragment, and its Ag, the term paratope is herein, unless otherwise specified or contradicted by context, specifically defined as Ag residues characterized by having a heavy atom (i.e. a non-hydrogen atom) within a distance of 4 Å from a heavy atom in NKG2A.
  • The epitope and paratope for a given antibody (Ab)/antigen (Ag) pair may be identified by routine methods. For example, the general location of an epitope may be determined by assessing the ability of an antibody to bind to different fragments or variant NKG2A polypeptides. The specific amino acids within NKG2A that make contact with an antibody (epitope) and the specific amino acids in an antibody that make contact with NKG2A (paratope) may also be determined using routine methods. For example, the antibody and target molecule may be combined and the Ab/Ag complex may be crystallised. The crystal structure of the complex may be determined and used to identify specific sites of interaction between the antibody and its target.
  • Antibodies binding to the same antigen can be characterized with respect to their ability to bind to their common antigen simultaneously and may be subjected to “binning”. In the present context the term “binning” refers to a method of grouping antibodies that bind to the same antigen. “Binning” of antibodies may be based on competition binding of two antibodies to their common antigen in assays based on standard techniques such as Surface Plasmon Resonance (SPR), ELISA or flow cytometry.
  • A “bin” is defined by a reference antibody. If a second antibody is unable to bind to the antigen at the same time as the reference antibody, the second antibody is said to belong to the same “bin” as the reference antibody. In this case the reference and the second antibody are competing for binding to the antigen, thus the pair of antibodies are termed “competing antibodies”. If a second antibody is capable of binding to the antigen at the same time as the reference antibody, the second antibody is said to belong to a separate “bin”. In this case the reference and the second antibody are not competing for binding to the antigen, thus the pair of antibodies is termed “non-competing antibodies”.
  • Antibody “binning” does not provide direct information about the epitope. Competing antibodies, i.e. antibodies belonging to the same “bin”, may have identical epitopes, overlapping epitopes or even separate epitopes. The latter is the case if the reference antibody bound to its epitope on the antigen takes up the space required for the second antibody to contact its epitope on the antigen (“steric hindrance”). Non-competing antibodies have separate epitopes.
  • The term “binding affinity” is herein used as a measure of the strength of a non-covalent interaction between two molecules, e.g. an antibody, or fragment thereof, and an antigen. The term “binding affinity” is used to describe monovalent interactions (intrinsic activity).
  • Binding affinity between two molecules, e.g. an antibody, or fragment thereof, and an antigen, through a monovalent interaction may be quantified by determination of the dissociation constant (KD). In turn, KD can be determined by measurement of the kinetics of complex formation and dissociation, e.g. by the SPR method. The rate constants corresponding to the association and the dissociation of a monovalent complex are referred to as the association rate constant ka (or kon) and dissociation rate constant kd (or koff), respectively. KD is related to ka and kd through the equation KD=kd/ka.
  • Following the above definition, binding affinities associated with different molecular interactions, such as comparison of the binding affinity of different antibodies for a given antigen, may be compared by comparison of the KD values for the individual antibody/antigen complexes.
  • Similarly, the specificity of an interaction may be assessed by determination and comparison of the KD value for the interaction of interest, such as a specific interaction between an antibody and an antigen, with the KD value of an interaction not of interest.
  • Typically, the KD for the antibody with respect to the target will be 2-fold, preferably 5-fold, more preferably 10-fold less than KD with respect to the other, non-target molecule such as unrelated material or accompanying material in the environment. More preferably, the KD will be 50-fold less, such as 100-fold less, or 200-fold less; even more preferably 500-fold less, such as 1,000-fold less, or 10,000-fold less.
  • The value of this dissociation constant can be determined directly by well-known methods, such as by standard assays to evaluate the binding ability of ligands such as antibodies towards targets which are known in the art and include, for example, ELISAs, Western blots, RIAs, and flow cytometry analysis. The binding kinetics and binding affinity of the antibody can also be assessed by standard assays known in the art, such as SPR.
  • A competitive binding assay can be conducted in which the binding of the antibody to the target is compared to the binding of the target by another ligand of that target, such as another antibody.
  • An antibody of the invention may have a KD for its target of 1×10−7M or less, 1×10−8M or less, 1×10−9M or less, 1×10−10M or less, 1×10−11M or less, or 1×10−12M or less. The KD of an antibody of the current invention may be less than 0.8 nM, such as less than 0.7 nM, less than 0.6 nM, less than 0.5 nM, less than 0.4 nM, less than 0.3 nM, less than 0.2 nM, less than 0.1 nM, less than 0.05 nM, less than 0.025 nM, or less than 0.015 nM, such as between 0.015 nM and 0 nM.
  • The term “identity”, as known in the art, refers to a relationship between the sequences of two or more polypeptides, as determined by comparing the sequences. In the art, “identity” also means the degree of sequence relatedness between polypeptides, as determined by the number of matches between strings of two or more amino acid residues. “Identity” measures the percent of identical matches between the smaller of two or more sequences with gap alignments (if any) addressed by a particular mathematical model or computer program (i.e., “algorithms”). Identity of related polypeptides can be readily calculated by known methods. Such methods include, but are not limited to, those described in Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M. Stockton Press, New York, 1991; and Carillo et al., SIAM J. Applied Math. 48, 1073 (1988).
  • Preferred methods for determining identity are designed to give the largest match between the sequences tested. Methods of determining identity are described in publicly available computer programs. Preferred computer program methods for determining identity between two sequences include the GCG program package, including GAP (Devereux et al., Nucl. Acid. Res. 12, 387 (1984); Genetics Computer Group, University of Wisconsin, Madison, Wis.), BLASTP, BLASTN, and FASTA (Altschul et al., J. Mol. Biol. 215, 403-410 (1990)). The BLASTX program is publicly available from the National Center for Biotechnology Information (NCBI) and other sources (BLAST Manual, Altschul et al. NCB/NLM/NIH Bethesda, Md. 20894; Altschul et al., supra). The well-known Smith Waterman algorithm may also be used to determine identity.
  • For example, using the computer algorithm GAP (Genetics Computer Group, University of Wisconsin, Madison, Wis.), two polypeptides for which the percent sequence identity is to be determined are aligned for optimal matching of their respective amino acids (the “matched span”, as determined by the algorithm). A gap opening penalty (which is calculated as 3 times the average diagonal; the “average diagonal” is the average of the diagonal of the comparison matrix being used; the “diagonal” is the score or number assigned to each perfect amino acid match by the particular comparison matrix) and a gap extension penalty (which is usually 1/10 times the gap opening penalty), as well as a comparison matrix such as PAM 250 or BLOSUM 62 are used in conjunction with the algorithm. A standard comparison matrix (see Dayhoff et al., Atlas of Protein Sequence and Structure, vol. 5, supp.3 (1978) for the PAM 250 comparison matrix; Henikoff et al., Proc. Natl. Acad. Sci USA 89, 10915-10919 (1992) for the BLOSUM 62 comparison matrix) is also used by the algorithm.
  • Preferred parameters for a peptide sequence comparison include the following:
  • Algorithm: Needleman et al., J. Mol. Biol. 48, 443-453 (1970); Comparison matrix: BLOSUM 62 from Henikoff et al., PNAS USA 89, 10915-10919 (1992); Gap Penalty: 12, Gap Length Penalty: 4, Threshold of Similarity: 0.
  • The GAP program is useful with the above parameters. The aforementioned parameters are the default parameters for peptide comparisons (along with no penalty for end gaps) using the GAP algorithm.
  • The term “similarity” is a related concept, but in contrast to “identity”, refers to a sequence relationship that includes both identical matches and conservative substitution matches. If two polypeptide sequences have, for example, (fraction ( 10/20)) identical amino acids, and the remainder are all non-conservative substitutions, then the percent identity and similarity would both be 50%. If, in the same example, there are 5 more positions where there are conservative substitutions, then the percent identity remains 50%, but the percent similarity would be 75% (fraction ( 15/20)). Therefore, in cases where there are conservative substitutions, the degree of similarity between two polypeptides will be higher than the percent identity between those two polypeptides.
  • A “receptor” is defined as a molecular structure present on the surface or inside of a cell. A receptor produces a characteristic cellular response, i.e. biological activity, when a ligand binds. A “ligand” for a receptor is defined as any molecule (e.g. peptide, polypeptide, carbohydrate, small molecule or ion) that selectively is capable of binding to the receptor. An agonistic ligand (“agonist”) is a ligand that upon binding to the receptor to some degree is capable of eliciting the characteristic response for the receptor. An antagonistic ligand (“antagonist”) is a ligand that has the ability to bind to the receptor and to some degree block the action of an agonist, e.g. the natural ligand of the receptor.
  • NKG2A (OMIM 161555, the entire disclosure of which is herein incorporated by reference) is a member of the NKG2 group of transcripts (Houchins, et al. (1991) J. Exp. Med. 173:1017-1020). NKG2A is encoded by 7 exons spanning 25 kb, showing some differential splicing. Together with CD94, NKG2A forms the heterodimeric inhibitory receptor CD94/NKG2A, found on the surface of subsets of NK cells, α/β T cells, γ/δ T cells, and NKT cells. Similar to inhibitory KIR receptors, it possesses an ITIM in its cytoplasmic domain. As used herein, “NKG2A” refers to any variant, derivative, or isoform of the NKG2A gene or encoded protein. Also encompassed are any nucleic acid or protein sequences sharing one or more biological properties or functions with wild type, full length NKG2A, and sharing at least 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or higher nucleotide or amino acid identity. Human NKG2A comprises 233 amino acids in 3 domains, with a cytoplasmic domain comprising residues 1-70, a transmembrane region comprising residues 71-93, and an extracellular region comprising residues 94-233, of the following sequence:
  • (SEQ ID NO: 1)
    MDNQGVIYSDLNLPPNPKRQQRKPKGNKSSILATEQEITYAELNLQKASQ
    DFQGNDKTYHCKDLPSAPEKLIVGILGIICLILMASVVTIVVIPSTLIQR
    HNNSSLNTRTQKARHCGHCPEEWITYSNSCYYIGKERRTWEESLLACTSK
    NSSLLSIDNEEEMKFLSIISPSSWIGVFRNSSHHPWVTMNGLAFKHEIKD
    SDNAELNCAVLQVNRLKSAQCGSSIIYHCKHKL.
  • HLA-E (OMIM 143010, the entire disclosure of which is herein incorporated by reference) is a nonclassical MHC molecule that is expressed on the cell surface and regulated by the binding of peptides derived from the signal sequence of other MHC class I molecules. HLA-E binds natural killer (NK) cells and some T cells, binding specifically to CD94/NKG2A, CD94/NKG2B, and CD94/NKG2C (see, e.g., Braud et al. (1998) Nature 391:795-799, the entire disclosure of which is herein incorporated by reference). Surface expression of HLA-E is sufficient to protect target cells from lysis by CD94/NKG2A+NK, T, or NKT cell clones. As used herein, “HLA-E” refers to any variant, derivative, or isoform of the HLA-E gene or encoded protein. Also encompassed are any nucleic acid or protein sequences sharing one or more biological properties or functions with wild type, full length HLA-E, and sharing at least 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or higher nucleotide or amino acid identity.
  • In the context of the present invention, “an agent that binds to human CD94/NKG2A receptor” or “an anti-NKG2A antibody” or “NKG2A binding antibody” refers to an any agent and/or antibody with detectable binding to human CD94/NKG2A receptor using any standard assay where the agent and/or antibody is incubated in the presence of CD94/NKG2A or NKG2A and binding detected via, e.g., radiolabels, physical methods such as mass spectrometry, or direct or indirect fluorescent labels detected using, e.g., cytofluorometric analysis (e.g. FACScan). Any amount of binding above the amount seen with a control, non-specific agent indicates that the agent binds to the target.
  • The term humanized Z270 or humZ270 or hZ270, as used herein, comprises the antibody (SEQ. ID. NO. 2 and SEQ. ID. NO. 3) disclosed in the patent publication WO08009545, which is hereby incorporated by reference into this application. The term humanized Z199 or humZ199, as used herein, comprises the antibody (SEQ. ID. NO. 4 and SEQ. ID. NO. 5) disclosed in the patent publication WO09092805 which is hereby incorporated by reference into this application.
  • “Protractive groups”/“half-life extending moieties” are herein understood as one or more chemical groups attached to one or more amino acid site chain functionalities such as —SH, —OH, —COOH, —CONH2, —NH2, or one or more N- and/or O-glycan structures and that can increase in vivo circulatory half-life of therapeutic proteins/peptides when conjugated to these proteins/peptides. Examples of “protractive groups” include but are not limited to: Biocompatible fatty acids and derivatives thereof, Hydroxyalkyl Starch (HAS) e.g. Hydroxyethyl Starch (HES), Polyethylene Glycol (PEG), Poly (Glyx-Sery)n (HAP), Hyaluronic acid (HA), Heparosan polymers (HEP), Phosphorylcholine-based polymers (PC polymer), Fleximers, Dextran, Polysialic acids (PSA), an Fc domain, Transferrin, Albumin, Elastin-like peptides, XTEN polymers, Albumin binding peptides, a CTP peptide, and any combination thereof.
  • The term “NKG2A Fc fusion protein” is herein meant to encompass NKG2A fused to an Fc domain that can be derived from any antibody isotype.
  • Inflammation is the complex biological response of tissues to a variety of stimuli, including pathogens, damaged cells, or irritants. Inflammation is a protective response by the organism to remove or isolate the injurious stimuli and initiate the healing process. Inflammation is not a synonym for infection-infection is invasion of an organism by an exogenous pathogen, while inflammation is the immune system's response to the pathogen.
  • Inflammation is a cascade of events involving multiple components, including the vasculature (e.g., endothelial cells, pericytes, smooth muscle cells), cells of the immune system (e.g., T and B lymphocytes, monocytes, dendritic cells, neutrophils), cell-derived soluble mediators (cytokines, chemokines) and also resident cells in the targeted tissue (e.g., epithelial cells, synovial fibroblasts, neuronal cells). Acute inflammation is of short duration (hours to days) and largely involves resident cells in tissue, migration of leukocytes and exudation of fluid and plasma proteins to site of inflammation. This results from changes in vascular flow, cell activation and cellular components that attract leukocytes from circulation into the site of injury. Chronic inflammation is of prolonged duration in which active inflammation, tissue destruction and attempt at repair proceed simultaneously. Chronic inflammation can result from persistent infection, prolonged and repeated exposure to toxic agents or autoimmunity, a phenomenon by which the body's immune cells attack their own tissues, causing damage.
  • Normally, the immune system is able to distinguish between the body's normal cells (or “self”) and foreign pathogens or abnormal cells (“non-self”). In some instances, the immune system loses the ability to recognize “self” as normal and inappropriately initiates a response against tissue or cells. This response stems from a loss of tolerance to self and is termed “autoimmunity”. The pathologies resulting from autoimmunity often have serious clinical consequences and are one of the major health problems in the world, especially in developed nations. Examples of such autoimmune diseases include rheumatoid arthritis (RA), psoriasis, psoriatic arthritis, systemic lupus erythematosus (SLE), lupus nephritis, type I diabetes, Graves' disease, inflammatory bowel disease (IBD), Crohn's disease (CD), ulcerative colitis (UC), irritable bowel syndrome, multiple sclerosis (MS), autoimmune myocarditis, Kawasaki disease, coronary artery disease, chronic obstructive pulmonary disease, interstitial lung disease, autoimmune thyroiditis, scleroderma, systemic sclerosis, osteoarthritis, atopic dermatitis, vitiligo, graft vs. host disease, Sjören's syndrome, autoimmune nephritis, Goodpasture syndrome, chronic inflammatory demyelinating polyneuropathy, allergy, asthma and other autoimmune diseases that are a result of either acute or chronic inflammation.
  • The process by which the immune system loses the ability to recognize “self” as normal, and the subsequent response directed against the tissue or cells, results in loss of tolerance, a state of “autoimmunity”. The pathologies resulting from autoimmunity often have serious clinical consequences and are one of the major health problems in the world.
  • Targeted biological therapeutics are now available for the treatment of certain autoimmune diseases and/or chronic inflammatory diseases. For example, patients with rheumatoid arthritis may be treated with anti-CD20, a TNF antagonist (soluble TNFR or anti-TNF-α); patients with psoriasis may be treated with anti-CD11a; patients with multiple sclerosis may be treated with INF-beta; patients with ulcerative colitis may be treated with anti-TNF-α; and patients with Crohn's disease may be treated with anti-TNF-α or anti-CD4 integrin. Unfortunately, a large number of patients that receive treatment with any one of these biologics can experience a variety of side effects, could fail to respond, and/or can develop neutralizing antibodies against the drug. There is still a need for alternative biological medicaments which specifically target pathologies, but which do not affect healthy cells/tissue, which result in fewer or less severe side effects, which may be used long-term and/or which do not result in the generation of neutralizing antibodies. The current invention relates to these unmet needs amongst patients with autoimmune and/or chronic inflammatory diseases, disclosing antibodies that are suitable for use in such treatment.
  • Rheumatoid arthritis (RA) is a systemic disease that affects the entire body and is one of the most common forms of arthritis. It is characterized by inflammation of the joints, which causes pain, stiffness, warmth, redness and swelling. This inflammation is a consequence of inflammatory cells invading the joints and releasing enzymes that may digest bone and cartilage. As a result this inflammation can lead to severe bone and cartilage damage and to joint deterioration and severe pain among other physiological effects. The involved joint can lose its shape and alignment, resulting in pain and loss of movement.
  • There are several animal models for rheumatoid arthritis known in the art. For example, in the collagen-induced arthritis (CIA) model, mice develop an inflammatory arthritis that resembles human rheumatoid arthritis. Since CIA shares similar immunological and pathological features with RA, this makes it a suitable model for screening potential human anti-inflammatory compounds. Efficacy in this model is measured by decrease in joint swelling. Efficacy in RA in the clinic is measured by the ability to reduce symptoms in patients which is measured as a combination of joint swelling, erythrocyte sedimentation rate, C-reactive protein levels and levels of serum factors.
  • Cartilage erosion or cartilage destruction associated with RA is mainly driven by subsets of Fibroblast-like synoviocytes (FLS) present in the synovial intimal lining. The FLS, sometimes also referred to as Type B synoviocytes or RA synovial fibroblasts (RASF), are of mesenchymal origin and play a key role by producing cytokines that perpetuate inflammation, and they are principal producers of proteases that contribute to cartilage destruction. In RS, FLS develop an aggressive phenotype capable of invading into the extracellular cartilage matrix and further exacerbating joint damage.
  • Cartilage erosion or cartilage destruction, as referred to in this application, is the loss or degradation of the cartilage tissue.
  • Bone resorption, the removal of osseous tissue by osteoclasts, is the unique function of the osteoclasts, which are specialized multinucleated cells derived from the monocyte cell lineage. Their differentiation is regulated by macrophage colony-stimulating factor, RANK ligand, and osteoprotegerin as well as multiple other mediators that may either positively or negatively regulate their differentiation, activation, and/or survival. The osteoclast develops a specialized cytoskeleton that permits it to establish an isolated microenvironment between itself and bone, wherein degradation of bone protein and minerals occurs by a process involving proton transport and enzyme release.
  • Bone erosion, as referred to in this application, is the loss of bone mass or bone mineral density that happens when there is a slight (or more than slight) but persistent elevation in the rate of bone resorption over the rate of bone formation.
  • Osteoarthritis (OA) is the most prevalent type of arthritis, particularly in adults 65 years and older. The disease is characterized by chronic degenerative arthropathy that frequently leads to chronic pain and disability. The reported incidence and prevalence rates of OA in specific joints vary widely, due to differences in the case definition of OA. For example, OA may be defined by radiographic criteria alone (radiographic OA), by typical symptoms (symptomatic OA), or by both. Using radiographic criteria, the distal and proximal interphalangeal joints of the hand have been identified as the joints most commonly affected, but they are the least likely to be symptomatic. In contrast, the knee and hip, which constitute the second and third most common locations of radiographic OA, respectively, are nearly always symptomatic. The first metatarsal phalangeal and carpometacarpal joints are also frequent sites of radiographic OA, while the shoulder, elbow, wrist and metacarpophalangeal joints rarely develop idiopathic OA.
  • Age is the most consistently identified risk factor for OA and prevalence rates rise steeply after age 50 in men and age 40 in women. OA is diagnosed by a triad of typical symptoms, physical findings and radiographic changes. The American College of Rheumatology has set forth classification criteria to aid in the identification of patients with symptomatic OA that include, but do not rely solely on, radiographic findings. Patients with early disease experience localized joint pain that worsens with activity and is relieved by rest, while those with severe disease may have pain at rest. Weight bearing joints may “lock” or “give way” due to internal derangement that is a consequence of advanced disease. Stiffness in the morning or following inactivity (“gel phenomenon”) rarely exceeds 30 minutes.
  • Physical findings in osteoarthritic joints include bony enlargement, crepitus, cool effusions, and decreased range of motion. Tenderness on palpation at the joint line and pain on passive motion are also common, although not unique to OA. Radiographic findings in OA (slide) include osteophyte formation, joint space narrowing, subchondral sclerosis and cysts. The presence of an osteophyte is the most specific radiographic marker, although it is indicative of relatively advanced disease.
  • Radiographs are considered the “gold standard” test for the diagnosis of OA, but radiographic changes are evident only relatively late in the disease. The need is great for a sensitive and specific biological marker that would enable early diagnosis of OA, and monitoring of its progression. Routine laboratory studies, such as sedimentation rates and c-reactive protein, are not useful as markers for OA, although a recent study suggests that elevation of CRP predicts more rapidly progressive disease. Several epitopes of cartilage components, however, have been described that offer some promise as markers of OA. For example, chondroitin sulfate epitope 846, normally expressed only in fetal and neonatal cartilage, has been observed in OA, but not normal adult, cartilage and synovial fluid. Along a similar vein, an epitope unique to type II collagen has been described in OA cartilage, and can be unmasked in vitro by exposing normal cartilage to MMPs. This epitope can be measured in blood and urine and may prove useful in diagnosing or monitoring OA progression. Elevated serum hyaluronan levels have also been shown by some to correlate with radiographic OA. The finding of elevated cartilage oligomeric protein (COMP) levels in synovial fluid after traumatic joint injury may portend development of OA in the injured joint. Other potential markers of OA are listed but are either not easily accessible or lack the sensitivity and specificity required to consider them as potential OA markers.
  • Clinical symptoms of inflammation, the presence of histological inflammation in OA synovial tissue and early cartilage lesions at the border of the inflamed synovium are strong indicators that synovitis is a pivotal factor in the pathogenesis of OA. The traditional view of OA as a cartilage only disease is obsolete. OA should now be considered to be a whole joint disease that includes the synovial tissue. Bone, cartilage and synovium communicate by way of cell-cell interactions, through the release of soluble mediators and via mechanical signals. Synovial inflammation, despite not being a prerequisite for the development of OA, is clearly involved in cartilage breakdown and thus in the progression of the disease. Targeting the inflammatory synovium should delay or prevent articular cartilage damage and the formation of osteophytes, especially in early OA.
  • Psoriatic arthritis is a type of inflammatory arthritis that occurs in a subset of patients with psoriasis. In these patients, the skin pathology/symptoms are accompanied by joint swelling, similar to that seen in rheumatoid arthritis. It features patchy, raised, red areas of skin inflammation with scaling. Psoriasis often affects the tips of the elbows and knees, the scalp, the navel, and around the genital areas or anus.
  • The term “psoriatic arthritis” denotes a heterogeneous group of arthritides ranging from peripheral monoarticular, oligoarticular and polyarticular disease, to axial skeletal involvement. Yet, despite this apparent clinical heterogeneity, these various presentations are unified in their occurrence in individuals with cutaneous manifestations of psoriasis, rheumatoid factor sero-negativity, similar human leukocyte antigen (HLA) associations and radiographic similarities.
  • Approximately 2% of the Caucasian population in North America has psoriasis. Of these, 5-7% are affected by an inflammatory arthritis in some form. Overall, men and women are affected with equal frequency, though the actual male:female ratio may vary depending upon the subset in question. The peak incidence is in the 4th through 6th decades. Psoriatic skin disease pre-dates the onset of arthritis in 70% of cases, presents coincident with arthritis in 15% of cases, and follows the onset of arthritis in 15% of cases.
  • The cause of psoriatic arthritis is unknown. Peripheral joint activity in psoriatic arthritis parallels cutaneous activity in ⅓ of cases, whereas activity of the skin and axial skeletal disease are likely to be discordant. Genetic factors appear to play an important role. There is a 70% concordance for psoriasis in monozygotic twins. There is a 50-fold increased risk of developing psoriatic arthritis in first-degree relatives of patients with the disease. There is a 2-fold increased risk of disease “transmission” by an affected father as compared to an affected mother. There are epidemiologic associations with the expression of both class I and class II HLA alleles. Environmental factors have been implicated. Streptococcal infection can precipitate the development of guttate psoriasis. HIV infection can present with both psoriasis and psoriatic arthritis, as well as worsen existing disease. Physical trauma has been reported to precipitate the development of arthritis, suggesting that psoriatic arthritis is the manifestation of a “deep Koebner phenomenon”. The inflammatory and autoimmune character of the disease is supported not only by the clinical presentation, but also by the role that T-cells and various cytokines have been demonstrated to play in both the initiation and perpetuation of disease activity.
  • Factors that may portend a worse prognosis include extensive skin involvement; a strong family history of psoriasis; female gender; disease onset at <20 years of age; expression of HLA-B27, -DR3 or -DR4 alleles; and polyarticular or erosive disease.
  • Osteoporosis (OP) is a disease of bones that leads to an impaired bone strength and increased risk of fracture (see e.g. Theill et al. (2002) Annu Rev Immunol 20:795-23). In osteoporosis the bone mineral density (BMD) is reduced and the bone microarchitecture is gradually deteriorating, As defined by the World Health Organization (WHO) the disease is defined by a bone mineral density that is 2.5 standard deviations or more below the mean peak bone mass (average of young, healthy adults). The disease may be classified as primary type 1, primary type 2, or secondary. The form of osteoporosis most common in women after menopause is referred to as primary type 1 or postmenopausal osteoporosis. Primary type 2 osteoporosis (or senile osteoporosis) occurs after age 75 and is seen in both females and males at a ratio of 2:1. Finally, secondary osteoporosis may arise at any age and affects men and women equally. This form of osteoporosis results from chronic predisposing medical problems or disease, or prolonged use of medications such as glucocorticoids. Bone resorption is a major pathological factor in postmenopausal osteoporosis. Rapid or relatively rapid loss of bone mass/bone mineral density is often caused by an increase in number of osteoclasts or by excessive osteoclast activity (Walsh et al. (2005) Immunol Rev 208:228-251).
  • Osteoporosis risks can be reduced with lifestyle changes (e.g. diet, exercise, fall prevention) and sometimes medication (e.g. calcium, vitamin D, bisphosphonates and several others).
  • The term “treatment”, as used herein, refers to the medical therapy of any human. Said subject is expected to have undergone physical examination by a medical practitioner, who has given a tentative or definitive diagnosis which would indicate that the use of said specific treatment is beneficial to the health of said human subject. The timing and purpose of said treatment may vary from one individual to another, according to the status quo of the subject's health. Thus, said treatment may be prophylactic, palliative, symptomatic and/or curative.
  • In terms of the present invention, prophylactic, palliative, symptomatic and/or curative treatments may represent separate aspects of the invention.
  • In one aspect, the present invention provides compositions and formulations comprising molecules of the invention, such as the antibodies, antigen binding fragments of antibodies, polynucleotides, vectors and cells described herein. For example, the invention provides a pharmaceutical composition that comprises one or more antibody or antigen binding fragment of antibodies of the invention, formulated together with a pharmaceutically acceptable carrier.
  • Accordingly, one object of the invention is to provide a pharmaceutical formulation comprising such an antibody which is present in a concentration from 0.25 mg/ml to 250 mg/ml, and wherein said formulation has a pH from 2.0 to 10.0. The formulation may further comprise a buffer system, preservative(s), tonicity agent(s), chelating agent(s), stabilizers and surfactants. The use of preservatives, isotonic agents, chelating agents, stabilizers and surfactants in pharmaceutical compositions is well-known to the skilled person. Reference may be made to Remington: The Science and Practice of Pharmacy, 19th edition, 1995.
  • In one embodiment, the pharmaceutical formulation is an aqueous formulation. Such a formulation is typically a solution or a suspension. The terms “aqueous formulation” is defined as a formulation comprising at least 50% w/w water. Likewise, the term “aqueous solution” is defined as a solution comprising at least 50% w/w water, and the term “aqueous suspension” is defined as a suspension comprising at least 50% w/w water.
  • In another embodiment, the pharmaceutical formulation is a freeze-dried formulation, to which the physician or the patient adds solvents and/or diluents prior to use.
  • In a further aspect, the pharmaceutical formulation comprises an aqueous solution of such an antibody, and a buffer, wherein the antibody is present in a concentration from 1 mg/ml or above, and wherein said formulation has a pH from about 2.0 to about 10.0.
  • An antibody of the invention may be administered parenterally, such as intravenously, such as intramuscularly, such as subcutaneously. Alternatively, an antibody of the invention may be administered via a non-parenteral route, such as perorally or topically. An antibody of the invention may be administered prophylactically. An antibody of the invention may be administered therapeutically (on demand).
  • In the context of the present invention “selective elimination of cartilage destructive cells” refers to a process in which an antibody against NKG2A increases NK cell mediated elimination of cartilage destructive cells, such as fibroblast-like synoviocytes (FLS) or other cartilage destructive cells, while not increasing the elimination of normal fibroblasts, such as e.g. foreskin fibroblasts (FSK4 cells) or other normal fibroblast cells. This selective elimination can be measured for example by a standard LDH release assay or other known suitable assays, in which the capacity of the therapeutic compound to eliminate the cartilage destructive cells is measured (see Example 4 and FIG. 5B). In one embodiment, an anti-NKG2A antibody causes at least 5% increase in the specific cytotoxicity of the cartilage destructive cells, or at least 10% increase in the specific cytotoxicity of the cartilage destructive cells. In one embodiment, an anti-NKG2A antibody causes at least 20% increase in the specific cytotoxicity of the cartilage destructive cells, or at least 30% increase in the specific cytotoxicity of the cartilage destructive cells. In one embodiment, an anti-NKG2A antibody causes at least 40% increase in the specific cytotoxicity of the cartilage destructive cells, or at least 50% increase in the specific cytotoxicity of the cartilage destructive cells. In one embodiment, an anti-NKG2A antibody causes at least 60% increase in the specific cytotoxicity of the cartilage destructive cells, or at least 70% increase in the specific cytotoxicity of the cartilage destructive cells. In one embodiment, an anti-NKG2A antibody causes at least 80% increase in the specific cytotoxicity of the cartilage destructive cells, or at least 90% increase in the specific cytotoxicity of the cartilage destructive cells. In one embodiment, an anti-NKG2A antibody causes at least 100% increase in the specific cytotoxicity of the cartilage destructive cells, or at least 125% increase in the specific cytotoxicity of the cartilage destructive cells. In one embodiment, an anti-NKG2A antibody causes at least 150% increase in the specific cytotoxicity of the cartilage destructive cells, or at least 175% increase in the specific cytotoxicity of the cartilage destructive cells. In one embodiment, an anti-NKG2A antibody causes at least 200% increase in the specific cytotoxicity of the cartilage destructive cells, or at least 225% increase in the specific cytotoxicity of the cartilage destructive cells. In one embodiment, an anti-NKG2A antibody causes at least 250% increase in the specific cytotoxicity of the cartilage destructive cells, or at least 275% increase in the specific cytotoxicity of the cartilage destructive cells. In one embodiment, an anti-NKG2A antibody causes at least 300% increase in the specific cytotoxicity of the cartilage destructive cells, or at least 350% increase in the specific cytotoxicity of the cartilage destructive cells. In one embodiment, an anti-NKG2A antibody causes at least 400% increase in the specific cytotoxicity of the cartilage destructive cells, or at least 500% increase in the specific cytotoxicity of the cartilage destructive cells.
  • In the context of the present invention “reduces formation of bone eroding cells” refers to a process in which an anti-NKG2A antibody reduces the formation of bone eroding cells, such as osteoclasts, TRAP+ multinucleated cells or other bone eroding cells.
  • The reduced formation of bone eroding cells can be measured in vitro by visual counting of adherent bone eroding cells (see Example 6. and FIG. 6C.) or any other suitable method of measuring the reduced formation of the bone eroding cells. In one embodiment an anti-NKG2A antibody causes at least 5% reduction of bone eroding cells or at least 10% reduction of bone eroding cells. In one embodiment an anti-NKG2A antibody causes at least 20% reduction of bone eroding cells or at least 30% reduction of bone eroding cells. In one embodiment an anti-NKG2A antibody causes at least 40% reduction of bone eroding cells or at least 50% reduction of bone eroding cells. In one embodiment an anti-NKG2A antibody causes at least 60% reduction of bone eroding cells or at least 70% reduction of bone eroding cells. In one embodiment an anti-NKG2A antibody causes at least 80% reduction of bone eroding cells or at least 90% reduction of bone eroding cells. In one embodiment an anti-NKG2A antibody causes at least 100% reduction of bone eroding cells or at least 125% reduction of bone eroding cells. In one embodiment an anti-NKG2A antibody causes at least 150% reduction of bone eroding cells or at least 175% reduction of bone eroding cells. In one embodiment an anti-NKG2A antibody causes at least 200% reduction of bone eroding cells or at least 225% reduction of bone eroding cells. In one embodiment an anti-NKG2A antibody causes at least 250% reduction of bone eroding cells or at least 275% reduction of bone eroding cells. In one embodiment an anti-NKG2A antibody causes at least 300% reduction of bone eroding cells or at least 350% reduction of bone eroding cells. In one embodiment an anti-NKG2A antibody causes at least 400% reduction of bone eroding cells or at least 450% reduction of bone eroding cells. In one embodiment an anti-NKG2A antibody causes at least 500% reduction of bone eroding cells.
  • Furthermore “reduces formation of bone eroding cells” in the context of present invention refers to reduced bone mineral erosion in vitro.
  • The reduced in vitro bone mineral erosion can be measured by culturing the cells or tissue on bone mineral discs (i.e. osteologic discs) or by other suitable methods. (See Example 6. and FIGS. 6D, 6E, 6F and 6G). In one embodiment an anti-NKG2A causes a 10% reduction in bone mineral erosion or 20% reduction in bone mineral erosion. In one embodiment an anti-NKG2A causes a 30% reduction in bone mineral erosion or 40% reduction in bone mineral erosion. In one embodiment an anti-NKG2A causes a 50% reduction in bone mineral erosion or 60% reduction in bone mineral erosion. In one embodiment an anti-NKG2A causes a 70% reduction in bone mineral erosion or 80% reduction in bone mineral erosion. In one embodiment an anti-NKG2A causes a 90% reduction in bone mineral erosion or 100% reduction in bone mineral erosion. In one embodiment an anti-NKG2A causes a 125% reduction in bone mineral erosion or 150% reduction in bone mineral erosion. In one embodiment an anti-NKG2A causes a 175% reduction in bone mineral erosion or 200% reduction in bone mineral erosion. In one embodiment an anti-NKG2A causes a 250% reduction in bone mineral erosion or 300% reduction in bone mineral erosion. In one embodiment an anti-NKG2A causes a 350% reduction in bone mineral erosion or 400% reduction in bone mineral erosion. In one embodiment an anti-NKG2A causes a 450% reduction in bone mineral erosion or 500% reduction in bone mineral erosion. In one embodiment an anti-NKG2A causes a 550% reduction in bone mineral erosion or 600% reduction in bone mineral erosion. In one embodiment an anti-NKG2A causes a 650% reduction in bone mineral erosion or 700% reduction in bone mineral erosion.
    • EXAMPLES Example 1. Cell Surface Molecules Expressed on Fibroblast-Like Synoviocytes from RA Patients
  • In FIG. 1A. adherent RA-FLS derived from RA synovial tissue were detached using 2 mM EDTA and surface stained for expression of fibroblast-marker CD55 (open histogram; right panel) and macrophage-marker CD68 (open histogram; left panel). The gray histogram represents the staining using an isotype control antibody. As seen in FIG. 1A, the RA-FLS show homogenous expression of CD55 and lack of CD68 confirms the fibroblast-like origin of adherent RA-FLS.
  • As shown in FIG. 1B. RA-FLS express high levels of ULBP-1, ULBP-2 and ULBP3, low levels of MIC-A, and no MIC-B, all known ligands for the activating NK cell receptor NKG2D. Furthermore, RA-FLS express CD155 (poliovirus receptor PVR) and CD48, ligands for DNAM-1 and 2B4, respectively. We did not detect any expression of CD112 (poliovirus-related receptor 2, PRR2), another ligand recognized by DNAM-1. Using Fc fusion proteins of NKp30, NKp44, and NKp46, we detected relatively high expression of a putative NKp44 ligand on RA-FLS, while NKp30-Fc and NKp46-Fc failed to stain these cells. Cells were analyzed by flow cytometry. Filled histograms represent relevant isotype control. Histograms are representative for n≥3 donors.
  • FIG. 1C. illustrates that the binding of soluble NKp44-Fc fusion protein to RA-FLS was specific and abolished by the addition of increasing doses of anti-NKp44 mAb. Adherent RA-FLS were detached using 2 mM EDTA, and surface stained with 10 ug/mL NKp44-Fc fusion protein (open histogram) or the same Fc fragment (human IgG1) as a negative control (gray histogram). Where indicated, NKp44-Fc was pre-incubated with anti-NKp44 or anti-NKp46 mAbs.
  • As demonstrated in FIG. 1D., RA-FLS express high levels of both HLA-E and HLA-G, ligands for the inhibitory NK cell receptors CD94-NKG2A and LIR-1, respectively. Thus, HLA-E may be an important molecule protecting RA-FLS from NK cell-mediated cytotoxicity in the inflamed synovium, as most synovial NK cells express the inhibitory CD94-NKG2A receptor.
  • In FIG. 1E. it is demonstrated that RA-FLS express death receptor 5 (DR5) but not DR4. These receptors transduce apoptotic signals upon recognition by TRAIL (TNF-related apoptosis-inducing ligand). Thus, DR5 may be an important ligand expressed on RA-FLS that can be recognized by TRAIL expressing cells that potentially can mediate RA-FLS cell death within the inflamed synovial tissue.
    • Example 2. NKG2A Expressing NK Cells are Present in RA Synovium and can be Found in Areas Containing HLA-E Expressing RA-FLS
  • FIGS. 2A, 2B, and 2C shows serial synovial tissue sections derived from a patient with RA stained with mouse anti-NKp46 (NK cells, FIG. 2A), anti-NKG2A (FIG. 2B) and isotype control antibody (FIG. 2C). Immune-specific reactivity was visualized with diaminobenzidine (dark spots in the micrograph) and nuclei were counterstained with hematoxylin (faint spots). The results show that NKp46+NK cells are found in the sublining area and a few closer to the synovial lining of RA synovium (see FIG. 2A). Localization and frequency of NK cells were found to be very similar to that of NKG2A+ cells (see FIG. 2B for comparison). Sections stained with isotype control were blank (see FIG. 2C.). When evaluated by quantitative digital image analysis, the frequency of NKG2A+ cells was found to correlate strongly (r2=0.950, p<0.0001) with and to match by number that of NK cells, as shown in FIG. 2D.
  • The expression of HLA-E, the ligand for CD94-NKG2A, on RA-FLS was evaluated in situ (FIGS. 2E-H). Application of the anti-HLA-E antibody 3D12 onto RA synovial tissue sections revealed staining of the intimal lining, which is made up of macrophage-like synoviocytes (MLS) and RA-FLS, as is shown in FIG. 2E. No staining is observed using an isotype control, as demonstrated in FIG. 2G. Furthermore, both infiltrating immune cells, shown in FIG. 2F., and vascular endothelial cells as shown in FIG. 2H. expressed HLA-E at relatively high levels.
  • Together, these data show that NK cells can be identified among the infiltrating lymphocyte population in the synovium of RA patients, and suggest that most, if not all, NK cells express NKG2A. Furthermore, subsets of NKG2A+NK cells are found in areas close to HLA-E+ RA-FLS. Thus, this could potentially mean that NKG2A+NK cells recognize HLA-E on RA-FLS in situ.
    • Example 3: NKG2D, DNAM-1, NKp44, NKp46, and TRAIL are Involved in NK Cell Cytotoxicity Towards RA-FLS
  • In FIG. 3A. three different types of NK cells that were stained for surface expression of several NK cell receptors are shown (as open histogram), as indicated below each histogram, and staining with a relevant isotype control is also shown in each panel (filled gray histogram). FIG. 3A. (i) shows NK cells derived from SFMC from a representative RA patient, FIG. 3A. (ii) shows resting CD56bright NK cells derived from PBMC from a representative healthy donor and FIG. 3A. (iii) shows Nishi NK cells.
  • Cells were analyzed by flow cytometry. NK cells were defined as viable CD3-CD56bright. The data shows that synovial NK cells derived from RA patients express several activating receptors, and that they show a similar expression pattern of activating receptors to CD56bright NK cells and Nishi NK cells.
  • FIG. 3B. (i) illustrates RA-FLS that were seeded at 10,000 cells/well in 48-well plates, and grown to confluency (˜48,000 cells/well) for 72 hours, at which point Nishi were added at the indicated effector:target (E:T) ratios (duplicate wells were set up). RA-FLS and Nishi were co-cultured overnight at 37° C., non-adherent cells were subsequently washed off and adherent cells were fixed with 4% paraformaldehyde and stained with Eosin. An ImmunoSpot Image Analyzer was used to take images and quantify the % well area covered (as shown in FIG. 3B. (ii)).
  • The data in FIG. 3B (i) and 3B(ii) shows that NK cells eliminate plastic-adherent RA-FLS in a dose-dependent manner in vitro.
  • In FIG. 3C. and FIG. 3D (i) demonstrate RA-FLS that were seeded at 30,000 cells/well in 96-well plates, and on the following day 90,000 Nishi/well were added. Nishi and FLS were co-cultured for 5 hours at 37° C. with BD GolgiStop, FITC-conjugated anti-CD107a/b antibodies and 10 ug/mL blocking antibodies, or relevant isotype control, as indicated. Flow cytometry was performed to determine Nishi degranulation. ns=not significant, * P<0.05, ** P<0.005, *** P<0.001.
  • FIG. 3C shows that NK cells only degranulate in the presence of FLS target cells and not when cultured alone. FIG. 3D shows that RA-FLS are sensitive to NK cell-mediated cytotoxicity, and that NKG2D, DNAM1, NKp44, NKp46 and TRAIL are all involved in the specific recognition of RA-FLS by NK cells as indicated by a significant reduction in CD107a/b expression upon masking such receptors.
    • Example 4: RA-FLS are Protected from NK Cell-Mediated Cytotoxicity by Expression of HLA-E Capable of Interacting with Inhibitory CD94-NKG2A Receptors Expressed by NK Cells
  • FIG. 4A shows representative histograms with NK cells from RA-SFMC in the top row, resting CD56bright NK cells from healthy PBMC in the middle row and Nishi NK cells in the bottom row. Expression of NKG2A (left column), LIR-1 (middle column) and KIRs (right column) is shown (open histograms) compared with corresponding isotype control (gray filled histograms). NK cells were stained for surface expression using anti-NKG2A, anti-LIR1, and a cocktail of anti-KIR mAbs and subsequently analyzed by flow cytometry. NK cells are gated on viable CD3 negative CD56bright positive cells.
  • The data show that most synovial fluid NK cells similar to Nishi NK cells and CD56bright PB-NK cells express NKG2A but lack KIRs. In contrast to synovial fluid NK cells, Nishi NK cells also express LIR-1.
  • FIG. 4B illustrates RA-FLS that were seeded at 3·104 cells/well in 96-well plates; the following day Nishi were added at an E:T ratio of 3:1 (anti-LIR-1 experiments, left panel) or 6:1 (anti-NKG2A experiments, right panel). Nishi and FLS were co-cultured for 5 hours at 37° C. with BD GolgiStop, FITC-conjugated anti-CD107a/b antibodies and 10 ug/mL blocking antibodies, or relevant isotype control, as indicated. Flow cytometry was performed to determine Nishi degranulation. ns=not significant, ** P<0.005, as shown in FIG. 4B.
  • The data shows that masking NKG2A with an antibody results in a significantly increased NK cell degranulation towards RA-FLS (right panel), while masking LIR-1 does not appear to result in any increased lysis of RA-FLS (left panel). Thus, the fact that anti-NKG2A treatment of NK cells results in increased lysis of RA-FLS indicates that HLA-E molecules expressed on RA-FLS present appropriate peptides important for interacting with CD94-NKG2A inhibitory receptors.
  • FIG. 4C demonstrates RA-FLS that were seeded at 2.4·104 cells/well in 96-well plates; the following day 6-103 Nishi NK cells/well were added (i.e. E:T of 1:4). FLS and Nishi were co-cultured overnight with the addition of anti-NKG2A or human IgG4 isotype control. The next day, non-adherent cells were washed off, adherent cells were fixed with 4% paraformaldehyde and stained with Eosin. Wells were analyzed, and % well area covered was quantified, using an ImmunoSpot Image Analyzer, as shown in FIG. 4C. Thus, the data show that masking NKG2A results in a significantly increased elimination of adherent RA-FLS.
  • RA-FLS were seeded at 1.5·104 cells/well in 96-well plates; the following day 4.5·104 autologous SFMC were added per well (i.e. E:T 3:1). SFMC and RA-FLS were co-cultured for 5 hours at 37° C. with BD GolgiStop, FITC-conjugated anti-CD107a/b antibodies and 10 ug/mL blocking antibodies, or human IgG4 isotype control, as shown in FIG. 4D.
  • Thus, masking NKG2A with mAb results in significantly increased elimination of autologous RA-FLS in vitro, suggesting that therapeutic administration of an anti-NKG2A mAb would result in increased elimination of RA-FLS in vivo.
  • FIG. 4E. shows 3-104 FLS/well that were seeded in 96-well plates. The following day, allogeneic CD56brightCD16dim NK cells were isolated from healthy donor blood by magnetic separation and immediately co-cultured with RA-FLS (E:T 3:1) for 5 hours at 37° C. with BD GolgiStop, FITC-conjugated anti-CD107a/b antibodies and 10 ug/mL blocking antibodies, or relevant isotype control. Flow cytometry was performed to determine degranulation. NK cells were defined as viable CD3-CD16dimCD56bright. The bottom graph shows CD56bright NK cells from a single healthy donor co-cultured separately with RA-FLS from five different patients. * P<0.05.
  • Thus, masking NKG2A with mAb on resting, freshly isolated PB-NK cells results in significantly increased elimination of allogeneic RA-FLS in vitro, again suggesting that therapeutic administration of an anti-NKG2A mAb would result in increased elimination of RA-FLS in vivo. Thus, aggressive disease spreading RA-FLS that may migrate through the bloodstream to other joints may be eliminated by circulating CD56bright PB-NK cells upon masking their CD94-NKG2A inhibitory receptor.
  • FIG. 5A shows an LDH release assay that was employed to assess NK cell-mediated cytotoxicity of FLS using two different NK cell lines (NKL, left; and Nishi, right) in the presence of NNC141-0100 (HumZ270, black bars), isotype control (white bars), or medium alone (gray bars). The NK cell effector to target ratio was 1:1. FIG. 5B shows that blocking NKG2A using NNC141-0100 (humZ270) leads to increased lysis of a representative RA-FLS (RA-FLS2, left panel) but does not affect elimination of a normal foreskin fibroblast cell line (FSK4, right panel). Thus, taken together the data presented in FIG. 3 , FIG. 4 , and FIG. 5 clearly suggest that anti-NKG2A treatment results in increased NK cell-mediated elimination of RA-FLS while the NK cell-mediated elimination of a normal fibroblast cell line (FSK4) is unaffected in the presence of a blocking antibody (i.e. HumZ270) directed against NKG2A.
    • Example 6: Treatment with humZ270 (Anti-NKG2A) Inhibits Formation of TRAP+ Multinucleated Osteoclasts
  • FIG. 6A shows a representative example where 106 SFMC/well derived from a RA patient were cultured for 7 days in medium supplemented with 10 ng/mL IL-15. Cultures were treated with 20 microgram/ml human IgG4 isotype control (FIG. 6A.) or 20 microgram/ml humZ270 (FIG. 6B.) at the beginning of the assay. It can be appreciated that anti-NKG2A treatment in FIG. 6B results in significant elimination of large plastic adherent multinucleated cells that express TRAP (i.e. defined as osteoclasts).
  • FIG. 6C demonstrates the data obtained from SFMC derived from RA patients that have been cultured for 7 days in medium alone (n=6) or medium supplemented with 10 ng/mL IL-15 (n=14). At the beginning of the assay (defined as baseline), 20 microgram/mL human IgG4 isotype (white and dark gray bars) or 20 microgram/mL NNC141-0100 (humZ270, light gray and black bars) were added to the cultures. Osteoclasts were quantitated as numbers of TRAP+ multinuclear cells/well. Thus, taken together FIG. 6A, FIG. 6B, and FIG. 6C shows that treatment with an antibody against NKG2A in SFMC in vitro cultures results in a significant reduction of osteoclast formation as measured by the formation of large multinucleated TRAP+ cells (i.e. osteoclasts). Thus, the findings suggest that therapeutic treatment in RA patients with anti-NKG2A mAb would result in dampening of bone erosion, a major clinical hallmark of RA.
  • In FIG. 6D a representative example of bone mineral erosion observed from an SFMC culture of RA patient no. 2357 is shown. Here SFMC were grown on discs coated with a thin layer of bone mineral substrate (i.e. osteologic discs) in the presence of IL-15 and isotype mAb (left) vs anti-NKG2A (humZ270, right). The discs were subsequently stained with von Kossa and eroded areas were analyzed using Immunospot S5 Analyzer and appear as light/white areas against the darker background.
  • In FIG. 6E data obtained from in total 5 RA patients is demonstrated. SFMC were cultured in medium supplemented with 10 ng/mL IL-15. At the beginning of the assay, 20 microgram/mL human IgG4 isotype (white bar) or 20 microgram/mL NNC141-0100 (humX270, black bar) were added to the cultures. The mean percentage+/−SEM eroded disc area was quantitated using Immunospot S5 Analyzer. Taken together, FIG. 6D and FIG. 6E show that anti-NKG2A treatment results in a significant reduction in the formation of active bone mineral eroding osteoclasts. Thus, the findings suggest that therapeutic treatment in RA patients with anti-NKG2A mAb would result in dampening of bone erosion, a major clinical hallmark of RA.
  • FIG. 6F illustrates that HumZ270 (anti-NKG2A) suppresses bone erosion in RA synovial tissue explant cultures cultured directly ex vivo. RA synovial tissue shavings were grown for 7 days in IMDM medium supplemented with 10% FBS, 2% HuS, P/S, L-glut without addition of mAbs (control) or with addition of isotype, infliximab (IFX), or anti-NKG2A (humZ270), all mAbs at 10 micrograms/mL added in the beginning of the culture. The experiment was set up in triplicate wells. At day 7, the medium and cells were removed by rinsing the wells 3× with 200 uL MILLIi-Q water. The discs were subsequently rinsed with 200 uL bleach solution (˜6% NaOCl, ˜5.2% NaCl) for 5 minutes followed by gentle pipetting to dislodge any remaining cells. Finally, the discs were washed 3× with MILLI-Q water, air-dried and stained with the von Kossa method. It can be appreciated from this example of triplicate cultures that humZ270 treatment of RA synovial tissue explants results in decreased erosion (light/white areas) as compared to control or isotype treated cultures.
  • In FIG. 6G the calculated results (mean+/−SEM) from triplicate cultures of RA synovial tissue shavings that have been grown for 7 days in IMDM medium supplemented with 10% FBS, 2% HuS, P/S, L-glut without addition of mAbs (control) or with addition of isotype, infliximab (IFX), or anti-NKG2A (humZ270), all mAbs at 10 micrograms/mL added in the beginning of the culture, are illustrated. At day 7, the medium and cells were removed by rinsing the wells 3× with 200 uL MILLI-Q water. The discs were subsequently rinsed with 200 uL bleach solution (˜6% NaOCl, ˜5.2% NaCl) for 5 minutes followed by gentle pipetting to dislodge any remaining cells. Finally, the discs were washed 3× with MILLI-Q water, air-dried and stained with the von Kossa method. HumZ270 treatment of RA synovial tissue explants results in significantly decreased erosion (p=0.005, Student's T test) as compared to control or isotype treated cultures. Thus, RA tissue growing directly ex vivo on discs coated with bone minerals (i.e. osteologic discs) show significant erosive capacity and such activity is drastically inhibited by treatment with anti-NKG2A, clearly suggesting that therapeutic treatment in RA patients with anti-NKG2A would suppress bone erosion, a major clinical hallmark of RA.
    • Example 7: Modulation of Cytokine Levels in SFMC In Vitro Cultures Upon Treatment with HumZ270 (NNC141-0100)
  • In FIG. 7A modulation of cytokine levels (mean+/−SEM) in in vitro cultures of SFMC derived from patients with RA (n=11) is demonstrated. SFMC were cultured for 7 days in medium supplemented with 10 ng/mL IL-15. Cultures were treated with 20 micrograms/mL human IgG4 isotype (light gray bars) or 20 micrograms/mL NNC141-0100 (humZ270, dark gray bars) at the beginning of the assay. Supernatant was harvested at 24 hours and the levels of cytokines were measured by BioPlex. The IL-6 levels are significantly reduced upon treatment with anti-NKG2A, while the production of other cytokines is not significantly affected, except for a small increase in M-CSF at 24 hours.
  • FIG. 7B shows a pairwise comparison between the IL-6 levels measured in RA-SFMC in vitro cultures stimulated with IL-15 and treated with isotype vs HumZ270 (anti-NKG2A). The IL-6 levels are significantly reduced upon masking NKG2A in all SFMC in vitro cultures.
  • In FIG. 7C it is demonstrated that NNC141-0100 (humZ270) inhibits both baseline and IL-15 stimulated IL-6 production in in vitro cultures of SFMC derived from patients with RA. IL-6 levels produced by SFMC derived from 2 patients with RA were measured in cultures established in medium alone or medium supplemented with 10 ng/mL IL-15 as indicated. Cultures were treated with 20 micrograms/mL human IgG4 isotype (black bars) or 20 micrograms/mL NNC141-0100 (humZ270, white bars) at the beginning of the assay. Supernatant was harvested at 24, 48 and 72 hours and the levels of IL-6 were measured by BioPlex. Taken together, FIGS. 7A, 7B, and 7C show that anti-NKG2A suppresses both baseline and stimulated IL-6 levels in SFMC in vitro cultures. IL-6 is an important pro-inflammatory cytokine involved in the RA pathogenesis. Potentially, the reduction in IL-6 plays a role in the observed reduction in osteoclast formation.
    • Example 8: NKG2A and/or its Ligand HLA-E is Expressed in Inflamed Synovium from RA, Osteoarthritis (OA) and Psoriatic Arthritis (PsA) Patients
  • NK cells present in RA synovial tissue express the inhibitory NKG2A receptor and are localized predominantly in lymphoid aggregates adjacent to synoviocytes that express HLA-E, the ligand for CD94-NKG2A. This is shown in FIG. 8 . where representative pictures of RA synovial tissue from two out of 15 donors are depicted (ID 1144-09: A, C, E, G, I and ID 1591-08: B, D, F, H, J). Serial sections of RA synovium were stained for NK cells with an anti-NKp46 antibody (FIGS. 8A. and 8B.), for NKG2A with the Z199 antibody (FIGS. 8C. and 8D.), for HLA-E with the 3D12 antibody (FIGS. 8E. and 8F.) and for T cells with an anti-CD3 antibody (FIGS. 8G. and 8H.). No staining was observed using an IgG2b isotype control antibody (FIGS. 8I. and 8J.). Immune-specific reactivity was visualized with diaminobenzidine (DAB) and nuclei were counterstained with hematoxylin (bars=100 μm). Arrowheads indicate lymphoid aggregates in sublining tissue with NKp46, NKG2A, HLA-E and CD3 expressing cell subsets. Arrows indicate HLA-E+ synoviocytes in hyperplastic synovial lining layer adjacent to lymphoid aggregates with NK cells. Asterisks indicate HLA-E+ vascular endothelial cells.
  • High magnification pictures of NKp46+NK cells (FIG. 8K.) and NKG2A+ cells (FIG. 8L.) in serial sections of RA synovium from a third donor (ID 1595-08) are shown to emphasize that the localization and frequency of NK cells were very similar to that of NKG2A+ cells. Digital image analysis was used to correlate the number of NKG2A+ cells in synovium from 15 RA patients with the number of NKp46+NK cells (FIG. 8M.). Results are expressed as number of cells per mm2 and show that the frequency of NKG2A+ cells strongly correlates with (r2=0.950, p<0.0001) and matches by number that of NK cells. NKG2A+ cells were present in the synovium of 13/15 RA patients.
  • Together, these data show that NK cells can be identified among the infiltrating lymphocyte population in the synovium of RA patients, and suggest that most, if not all, NK cells express NKG2A. The ligand for CD94-NKG2A, HLA-E, is expressed by many infiltrating immune cells, vascular endothelial cells and synoviocytes (macrophage-like synoviocytes (MLS) and RA-FLS). Subsets of NKG2A+NK cells are found in areas close to HLA-E+ synoviocytes. Thus, this could potentially mean that NKG2A+NK cells recognize HLA-E on RA-FLS in situ. Moreover, HLA-E+ infiltrating immune cells and vascular endothelium may also be recognized by NKG2A* NK cells.
  • NKG2A and its ligand, HLA-E, are expressed in synovium of patients with osteoarthritis (OA). This is shown in FIG. 9 ., which depicts NKG2A* cells (Z199 antibody) among infiltrating lymphocytes (FIG. 9A.) and HLA-E expression (3D12 antibody) by infiltrating immune cells, endothelial cells and synoviocytes (FIG. 9B.). NKG2A+ cells were present in the synovium of 6/9 OA patients. In contrast to RA patients, the frequency of NKG2A+ cells does not seem correlate with that of NK cells in OA synovium, when quantified by digital image analysis (r2=0.136, p=0.3295; FIG. 9C.), indicating that some of the NK cells that infiltrate OA synovium may not express NKG2A.
  • Together, these data show expression of NKG2A and HLA-E in OA synovial cell subsets similar to those of RA synovium. Thus, NKG2A+NK cells may recognize HLA-E+ synoviocytes, vascular endothelium and infiltrating immune cells in inflamed synovium of OA patients.
  • The ligand for CD94-NKG2A, HLA-E, was found to be expressed in inflamed synovium from not only RA and OA, but also psoriatic arthritis (PsA) patients. This is shown in FIG. 10 . which depicts staining of synovial tissue samples from RA, OA and PsA patients (as indicated) with the anti-HLA-E antibody mAb MEM-E/02. In synovium of normal controls, HLA-E expression is observed in vascular endothelium and, more weakly, in subsets of synoviocytes located in the synovial lining, as indicated in FIG. 10 .
  • These data show expression of HLA-E by synoviocytes, vascular endothelium and infiltrating immune cells in inflamed synovium of PsA patients, meaning that NKG2A+ cells may recognize such HLA-E+cell subsets in these patients.
  • While certain features of the invention have been illustrated and described herein, many modifications, substitutions, changes, and equivalents will now occur to those of ordinary skill in the art. It is, therefore, to be understood that the appended claims are intended to cover all such modifications and changes as fall within the true spirit of the invention.
    • EMBODIMENTS
      • 1. An anti-NKG2A antibody, or an antigen binding fragment thereof, for the treatment of cartilage destruction and/or bone erosion.
      • 2. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to embodiment 1, for the treatment of a disease or disorder where reduction of cartilage destruction and/or bone erosion is beneficial to the patient.
      • 3. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to embodiment 1 or 2, wherein said anti-NKG2A antibody stimulates selective elimination of cartilage destructive cells and/or reduces formation of bone eroding cells.
      • 4. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to any of the preceding embodiments, wherein selective elimination of cartilage destructive cells and/or reduction of bone erosive cells is beneficial to the patient.
      • 5. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to any of the preceding embodiments, wherein the cartilage destructive cells are fibroblast-like synoviocytes (FLS).
      • 6. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to any of embodiments 1-5, wherein the bone eroding cells are osteoclasts.
      • 7. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to embodiment 6, wherein the bone eroding osteoclasts are TRAP+ multinucleated cells.
      • 8. An anti-NKG2A antibody, or antigen binding fragment thereof, according to any of the preceding embodiments, for the treatment of a disease or disorder characterised by cartilage destruction and/or bone erosion.
      • 9. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to embodiment 8, wherein the disease or disorder is osteoarthritis.
      • 10. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to embodiment 8, wherein the disease or disorder is osteoporosis.
      • 11. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to embodiment 8, wherein the disease or disorder is psoriatic arthritis.
      • 12. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to embodiment 8, wherein the disease or disorder is rheumatic arthritis.
      • 13. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to any of the preceding embodiments, wherein said antibody is an antigen binding fragment thereof.
      • 14. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to embodiment 13, wherein the antibody fragment is selected from a Fab, a Fab′, a F(ab)2, a F(ab′)2, a F(ab)3, an Fv, a single-chain Fv, a dsFv, an Fd fragment, a dAb fragment, a minibody, a diabody, a triabody, a tetrabody, a kappa body, a camel IgG, an IgNAR, and a multispecific antibody fragment.
      • 15. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to any of the preceding embodiments, wherein said antibody is a Fab fragment.
      • 16. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to any of the preceding embodiments, wherein said antibody is a bispecific antibody.
      • 17. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to any of the preceding embodiments, wherein said antibody is conjugated to a half-life extending moiety.
      • 18. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to any of the preceding embodiments, wherein said half-life extending moiety comprises one or more half-life extending moieties selected from one or more of the list consisting of: fatty acids and derivatives thereof, Hydroxyethyl Starch (HES), Polyethylene Glycol (PEG), hyaluronic acid (HA), heparosan polymers, Phosphorylcholine-based polymers, fleximers, dextran, poly-sialic acids (PSA), an Fc domain, transferrin, albumin, Elastin-like peptides, XTEN polymers, albumin binding peptides, and any combination thereof.
      • 19. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to embodiment 18, wherein the antibody can be conjugated with two or more different types of half-life extending moieties.
      • 20. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to any of the preceding embodiments, wherein said antibody comprises a mutated Fc domain, wherein said mutations result in reduced Fcγ receptor binding functions.
      • 21. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to embodiment 20, wherein said Fc domain comprises one or more of the following mutations: L234A, L235E, and G237A, A330S and P331S (according to the Kabat numbering scheme).
      • 22. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to any of the preceding embodiments, wherein said antibody comprises an IgG4 Fc domain.
      • 23. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to embodiment 22, wherein said IgG4 Fc domain comprises the S241P/S228P mutation.
      • 24. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to any of the preceding embodiments, wherein said antibody is a full-length IgG4 antibody or fragment thereof.
      • 25. An anti-NKGA antibody, or an antigen binding fragment thereof, according to any of the preceding embodiments, wherein said antibody is a humanized or human antibody.
      • 26. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to embodiment 25, wherein said antibody is humZ270 or humZ199.
      • 27. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to embodiment 25 or 26, wherein said antibody is humZ270.
      • 28. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to any of embodiments 25-27, wherein the heavy chain of said antibody comprises:
        • a CRD1 sequence of amino acid residues 31 to 35 (SYWMN) of SEQ. ID. NO:2, wherein one or two of these amino acid residues may be substituted by a different amino acid residue; and/or
        • a CRD2 sequence of amino acids 50-59 (RIDPYDSETH) of SEQ. ID. NO: 2, wherein one, two or three of these amino acid residues may be substituted by a different amino acid residue; and/or
        • a CDR3 sequence of amino acids 95-102 (YCARGGYD) of SEQ. ID. NO: 2, wherein one, two or three of these amino acid residues may be substituted by a different amino acid.
      • 29. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to any of embodiments 25-28, wherein the light chain of said antibody comprises:
        • a CDR1 sequence of amino acid residues 24-34 (RASENIYSYLA) of SEQ. ID. NO: 3, wherein one, two or three of these amino acid residues may be substituted with a different amino acid; and/or
        • a CDR2 sequence of amino acid residues 50-56 (NAKTLAE) of SEQ. ID. NO: 3, wherein one or two of these amino acid residues may be substituted with a different amino acid; and/or
        • a CDR3 sequence of amino acid residues 89-97 (QHHYGTPRT) of SEQ. ID. NO: 3, wherein one, two or three of these amino acid residues may be substituted with a different amino acid.
      • 30. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to any of embodiments 25-29, wherein the heavy chain of said antibody comprises:
        • a CRD1 sequence of amino acid residues 31 to 35 (SYWMN) of SEQ. ID. NO:2; and/or
        • a CRD2 sequence of amino acids 50-59 (RIDPYDSETH) of SEQ. ID. NO: 2; and/or
        • a CDR3 sequence of amino acids 95-102 (YCARGGYD) of SEQ. ID. NO: 2.
      • 31. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to any of embodiments 25-30, wherein the light chain of said antibody comprises:
        • a CDR1 sequence of amino acid residues 24-34 (RASENIYSYLA) of SEQ. ID. NO: 3; and/or
        • a CDR2 sequence of amino acid residues 50-56 (NAKTLAE) of SEQ. ID. NO: 3; and/or
        • a CDR3 sequence of amino acid residues 89-97 (QHHYGTPRT) of SEQ. ID. NO: 3.
      • 32. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to any of embodiments 25-31, wherein the heavy chain of said antibody comprises:
        • a CRD1 sequence of amino acid residues 31 to 35 (SYWMN) of SEQ. ID. NO:2; and/or
        • a CRD2 sequence of amino acids 50-59 (RIDPYDSETH) of SEQ. ID. NO: 2; and/or
        • a CDR3 sequence of amino acids 95-102 (YCARGGYD) of SEQ. ID. NO: 2; and wherein the light chain of said antibody comprises:
        • a CDR1 sequence of amino acid residues 24-34 (RASENIYSYLA) of SEQ. ID. NO: 3; and/or
        • a CDR2 sequence of amino acid residues 50-56 (NAKTLAE) of SEQ. ID. NO: 3; and/or
        • a CDR3 sequence of amino acid residues 89-97 (QHHYGTPRT) of SEQ. ID. NO: 3.
      • 33. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to any of embodiments 25-32, wherein the heavy chain of said antibody comprises SEQ. ID. NO: 2 and the light chain of said antibody comprises SEQ. ID. NO: 3.
      • 34. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to any of embodiments 1-24, that competes with the antibody of any of embodiments 25-33 for binding to NKG2A.
      • 35. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to embodiment 25 or 26, wherein said antibody is humZ199.
      • 36. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to either of embodiments 25-26 or embodiment 35, wherein the heavy chain of said antibody comprises:
        • a CRD1 sequence of amino acid residues 31 to 35 (SYAMS) of SEQ. ID. NO:4, wherein one or two of these amino acid residues may be substituted by a different amino acid residue; and/or
        • a CRD2 sequence of amino acids 50-65 (EISSGGSYTYYADSVK) of SEQ. ID. NO: 4, wherein one, two, three or four of these amino acid residues may be substituted by a different amino acid residue; and/or
        • a CDR3 sequence of amino acids 99-108 (HGDYPRFFDV) of SEQ. ID. NO: 4, wherein one, two or three of these amino acid residues may be substituted by a different amino acid.
      • 37. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to any of embodiments 25-26 or 35-36, wherein the light chain of said antibody comprises:
        • a CDR1 sequence of amino acid residues 24-34 (SASSSVSSYIY) of SEQ. ID. NO: 5, wherein one, two or three of these amino acid residues may be substituted with a different amino acid; and/or
        • a CDR2 sequence of amino acid residues 50-56 (LTSNLAS) of SEQ. ID. NO: 5, wherein one or two of these amino acid residues may be substituted with a different amino acid; and/or
        • a CDR3 sequence of amino acid residues 89-97 (QQWSGNPYT) of SEQ. ID. NO: 5, wherein one, two or three of these amino acid residues may be substituted with a different amino acid.
      • 38. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to any of embodiments 25-26 or 35-37, wherein the heavy chain of said antibody comprises:
        • a CRD1 sequence of amino acid residues 31 to 35 (SYAMS) of SEQ. ID. NO:4; and/or
        • a CRD2 sequence of amino acids 50-65 (EISSGGSYTYYADSVK) of SEQ. ID. NO: 4; and/or
        • a CDR3 sequence of amino acids-108 (HGDYPRFFDV) of SEQ. ID. NO: 4.
      • 39. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to any of embodiments 25-26 or 35-38, wherein the light chain of said antibody comprises:
        • a CDR1 sequence of amino acid residues 24-34 (SASSSVSSYIY) of SEQ. ID. NO: 5; and/or
        • a CDR2 sequence of amino acid residues 50-56 (LTSNLAS) of SEQ. ID. NO: 5; and/or
        • a CDR3 sequence of amino acid residues-97 (QQWSGNPYT) of SEQ. ID. NO: 5.
      • 40. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to any of embodiments 25-26 or 35-39, wherein the heavy chain of said antibody comprises:
        • a CRD1 sequence of amino acid residues 31 to 35 (SYWMN) of SEQ. ID. NO:2; and/or
        • a CRD2 sequence of amino acids 50-59 (RIDPYDSETH) of SEQ. ID. NO: 2; and/or
        • a CDR3 sequence of amino acids 95-102 (YCARGGYD) of SEQ. ID. NO: 2; and wherein the light chain of said antibody comprises:
        • a CDR1 sequence of amino acid residues 24-34 (RASENIYSYLA) of SEQ. ID. NO: 3; and/or
        • a CDR2 sequence of amino acid residues 50-56 (NAKTLAE) of SEQ. ID. NO: 3; and/or
        • a CDR3 sequence of amino acid residues 89-97 (QHHYGTPRT) of SEQ. ID. NO: 3.
      • 41. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to any of embodiments 25-26 or 35-40, wherein the heavy chain of said antibody comprises SEQ. ID. NO: 4 and the light chain of said antibody comprises SEQ. ID. NO: 5.
      • 42. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to any of embodiments 1-25 that competes with the antibody of any of embodiments 35-41 for binding to NKG2A.
      • 43. The use the anti-NKG2A antibody of any of the embodiments 1-7 or 13-42 for the treatment of cartilage destruction and/or bone erosion.
      • 44. The use of the anti-NKG2A antibody of embodiment 43 for the treatment of a disease or disorder characterized by cartilage destruction and/or bone erosion.
      • 45. The use of the anti-NKG2A antibody of embodiment 44, wherein the disease for disorder is osteoarthritis.
      • 46. The use of the anti-NKG2A antibody of embodiment 44, wherein the disease or disorder is osteoporosis.
      • 47. The use of the anti-NKG2A antibody of embodiment 44, wherein the disease or disorder is psoriatic arthritis.
      • 48. The use of the anti-NKG2A antibody of embodiment 44, wherein the disease or disorder is rheumatic arthritis.
      • 49. Method of treating a disease or disorder characterized by cartilage destruction and/or bone erosion, which comprises administering the anti-NKG2A antibody of any of the preceding embodiments to a patient.
      • 50. Method of treating a disease or disorder characterized by cartilage destruction, which comprises administering the anti-NKG2A antibody of any of embodiments 1-49 to a patient.
      • 51. Method of treating a disease or disorder characterized by bone erosion, which comprises administering the anti-NKG2A antibody of any of embodiments 1-49 to a patient.
      • 52. Method of treating a disease of disorder characterized by cartilage destruction and bone erosion, which comprises administering the anti-NKG2A antibody of any of embodiments 1-49 to a patient.
      • 53. An anti-NKG2A antibody, or an antigen binding fragment thereof, according to any of embodiments 1-49 for use as a medicament.
      • 54. An anti-NKG2A antibody, or an antigen binding fragment thereof pharmaceutical formulation comprising the antibody according to any one of embodiments 1-49.
      • 55. Use of the anti-NKG2A antibody, or an antigen binding fragment thereof, according to any one of embodiments 1-49 for the manufacture of a medicament.
  • All references, including publications, patent applications and patents, cited herein are hereby incorporated by reference to the same extent as if each reference was individually and specifically indicated to be incorporated by reference and was set forth in its entirety herein.
  • All headings and sub-headings are used herein for convenience only and should not be construed as limiting the invention in any way.
  • Any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
  • Unless otherwise expressly indicated or clearly contradicted by context, the term “or” herein is used in the inclusive sense of “and/or”, and, accordingly, as implicitly providing support for an embodiment or aspect in which the term is to be interpreted in the exclusive sense of “either this or that”.
  • The terms “a” and “an” and “the” and similar referents as used in the context of describing the invention are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context.
  • Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. Unless otherwise stated, all exact values provided herein are representative of corresponding approximate values (e.g., all exact exemplary values provided with respect to a particular factor or measurement can be considered to also provide a corresponding approximate measurement, modified by “about,” where appropriate).
  • All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context.
  • The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise indicated. No language in the specification should be construed as indicating any element is essential to the practice of the invention unless as much is explicitly stated.
  • The citation and incorporation of patent documents herein is done for convenience only and does not reflect any view of the validity, patentability and/or enforceability of such patent documents.
  • The description herein of any aspect or embodiment of the invention using terms such as “comprising”, “having”, “including” or “containing” with reference to an element or elements is intended to provide support for a similar aspect or embodiment of the invention that “consists of”, “consists essentially of”, or “substantially comprises” that particular element or elements, unless otherwise stated or clearly contradicted by context (e.g., a composition described herein as comprising a particular element should be understood as also describing a composition consisting of that element, unless otherwise stated or clearly contradicted by context).
  • This invention includes all modifications and equivalents of the subject matter recited in the aspects or claims presented herein to the maximum extent permitted by applicable law.

Claims (18)

1-21. (canceled)
22. A method for treating a subject having psoriatic arthritis, the method comprising administering an anti-NKG2A antibody, or an antigen binding fragment thereof to said subject, wherein said antibody blocks inhibitory signaling by CD94-NKG2A receptors and is a non-depleting antibody, and wherein said antibody has a heavy chain comprising the CDR1, CDR2 and CDR3 of SEQ ID NO: 2 and a light chain comprising the CDR1, CDR2 and CDR3 of SEQ ID NO: 3, or wherein said antibody has a heavy chain comprising the CDR1, CDR2 and CDR3 of SEQ ID NO: 4 and a light chain comprising the CDR1, CDR2 and CDR3 of SEQ ID NO: 5.
23. The method of claim 22, wherein the anti-NKG2A antibody stimulates selective elimination of cartilage destructive cells or reduces formation of bone eroding cells.
24. The method of claim 23, wherein the cartilage destructive cells are fibroblast-like synoviocytes (FLS).
25. The method of claim 23, wherein the bone eroding cells are osteoclasts.
26. The method of claim 22, wherein the anti-NKG2A antibody is a humanized or human antibody.
27. The method of claim 26, wherein the anti-NKG2A antibody is humZ270 or humZ199.
28. The method of claim 22, wherein the anti-NKG2A antibody comprises a heavy chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 2 and a light chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 3.
29. The method of claim 22, wherein the heavy chain of the anti-NKG2A antibody comprises:
a CDR1 sequence of amino acid residues 31 to 35 (SYAMS) of SEQ ID NO: 4, wherein one or two of these amino acid residues may be substituted by a different amino acid residue; and/or
a CDR2 sequence of amino acids 50-65 (EISSGGSYTYYADSVK) of SEQ ID NO: 4, wherein one, two, three or four of these amino acids residues may be substituted by a different amino acid residue; and/or
a CDR3 sequence of amino acids 99-108 (HGDYPRFFDV) of SEQ ID NO: 4, wherein one, two or three of these amino acids residues may be substituted by a different amino acid;
and wherein the light chain of said anti-NKG2A antibody comprises:
a CDR1 sequence of amino acid residues 24-34 (SASSSVSSYIY) of SEQ ID NO: 5, wherein one, two or three of these amino acid residues may be substituted with a different amino acid; and/or
a CDR2 sequence of amino acid residues 50-56 (LTSNLAS) of SEQ ID NO: 5, wherein one or two of these amino acid residues may be substituted with a different amino acid; and/or
a CDR3 sequence of amino acid residues 89-97 (QQWSGNPYT) of SEQ ID NO: 5, wherein one, two or three of these amino acid residues may be substituted with a different amino acid.
30. The method of claim 22, wherein the anti-NKG2A antibody comprises a heavy chain comprising SEQ ID NO: 2 and a light chain comprising SEQ ID NO: 3.
31. The method of claim 22, wherein the anti-NKG2A antibody comprises a heavy chain comprising SEQ ID NO: 4 and a light chain comprising SEQ ID NO: 5.
32. A method for treating psoriatic arthritis comprising administering an anti-NKG2A antibody, or an antigen binding fragment thereof, to a subject in need thereof, wherein said antibody has a heavy chain comprising the CDR1, CDR2 and CDR3 of SEQ ID NO: 2 and a light chain comprising the CDR1, CDR2 and CDR3 of SEQ ID NO: 3, or wherein said antibody has a heavy chain comprising the CDR1, CDR2 and CDR3 of SEQ ID NO: 4 and a light chain comprising the CDR1, CDR2 and CDR3 of SEQ ID NO: 5.
33. The method of claim 32, wherein the anti-NKG2A antibody is a humanized or human antibody.
34. The method of claim 33, wherein the anti-NKG2A antibody is humZ270 or humZ199.
35. The method of claim 32, wherein the anti-NKG2A antibody comprises a heavy chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 2 and a light chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 3.
36. The method of claim 32, wherein the heavy chain of the anti-NKG2A antibody comprises:
a CDR1 sequence of amino acid residues 31 to 35 (SYAMS) of SEQ ID NO: 4, wherein one or two of these amino acid residues may be substituted by a different amino acid residue; and/or
a CDR2 sequence of amino acids 50-65 (EISSGGSYTYYADSVK) of SEQ ID NO: 4, wherein one, two, three or four of these amino acids residues may be substituted by a different amino acid residue; and/or
a CDR3 sequence of amino acids 99-108 (HGDYPRFFDV) of SEQ ID NO: 4, wherein one, two or three of these amino acids residues may be substituted by a different amino acid;
and wherein the light chain of said anti-NKG2A antibody comprises:
a CDR1 sequence of amino acid residues 24-34 (SASSSVSSYIY) of SEQ ID NO: 5, wherein one, two or three of these amino acid residues may be substituted with a different amino acid; and/or
a CDR2 sequence of amino acid residues 50-56 (LTSNLAS) of SEQ ID NO: 5, wherein one or two of these amino acid residues may be substituted with a different amino acid; and/or
a CDR3 sequence of amino acid residues 89-97 (QQWSGNPYT) of SEQ ID NO: 5, wherein one, two or three of these amino acid residues may be substituted with a different amino acid.
37. The method of claim 32, wherein the anti-NKG2A antibody comprises a heavy chain comprising SEQ ID NO: 2 and a light chain comprising SEQ ID NO: 3.
38. The method of claim 32, wherein the anti-NKG2A antibody comprises a heavy chain comprising SEQ ID NO: 4 and a light chain comprising SEQ ID NO: 5.
US18/321,810 2011-06-17 2023-05-23 Selective elimination of erosive cells Pending US20230416374A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US18/321,810 US20230416374A1 (en) 2011-06-17 2023-05-23 Selective elimination of erosive cells

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP11170402.9 2011-06-17
EP11170402 2011-06-17
US201161501533P 2011-06-27 2011-06-27
PCT/EP2012/061583 WO2012172102A1 (en) 2011-06-17 2012-06-18 Selective elimination of erosive cells
US201414124876A 2014-02-24 2014-02-24
US15/355,087 US20170073417A1 (en) 2011-06-17 2016-11-18 Selective elimination of erosive cells
US16/718,935 US11697687B2 (en) 2011-06-17 2019-12-18 Selective elimination of erosive cells
US18/321,810 US20230416374A1 (en) 2011-06-17 2023-05-23 Selective elimination of erosive cells

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US16/718,935 Continuation US11697687B2 (en) 2011-06-17 2019-12-18 Selective elimination of erosive cells

Publications (1)

Publication Number Publication Date
US20230416374A1 true US20230416374A1 (en) 2023-12-28

Family

ID=44904625

Family Applications (4)

Application Number Title Priority Date Filing Date
US14/124,876 Active US9512228B2 (en) 2011-06-17 2012-06-18 Selective elimination of erosive cells
US15/355,087 Abandoned US20170073417A1 (en) 2011-06-17 2016-11-18 Selective elimination of erosive cells
US16/718,935 Active 2034-05-28 US11697687B2 (en) 2011-06-17 2019-12-18 Selective elimination of erosive cells
US18/321,810 Pending US20230416374A1 (en) 2011-06-17 2023-05-23 Selective elimination of erosive cells

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US14/124,876 Active US9512228B2 (en) 2011-06-17 2012-06-18 Selective elimination of erosive cells
US15/355,087 Abandoned US20170073417A1 (en) 2011-06-17 2016-11-18 Selective elimination of erosive cells
US16/718,935 Active 2034-05-28 US11697687B2 (en) 2011-06-17 2019-12-18 Selective elimination of erosive cells

Country Status (11)

Country Link
US (4) US9512228B2 (en)
EP (1) EP2721068B1 (en)
JP (1) JP6334395B2 (en)
KR (1) KR102047248B1 (en)
CN (1) CN103635487B (en)
AU (1) AU2012268939B2 (en)
BR (1) BR112013032217B1 (en)
CA (1) CA2838220C (en)
MX (1) MX342131B (en)
RU (1) RU2617056C2 (en)
WO (1) WO2012172102A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2591059C (en) 2004-12-28 2018-11-06 Innate Pharma Monoclonal antibodies against nkg2a
CN107693791B (en) 2010-02-26 2022-06-07 诺沃—诺迪斯克有限公司 Compositions comprising stable antibodies
WO2012172102A1 (en) 2011-06-17 2012-12-20 Novo Nordisk A/S Selective elimination of erosive cells
CN113929782B (en) 2014-09-16 2024-06-21 依奈特制药公司 Neutralization of inhibitory pathways in lymphocytes
JP2017538660A (en) 2014-09-16 2017-12-28 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Treatment plan using anti-NKG2A antibody
EP3659625A1 (en) 2014-10-23 2020-06-03 Innate Pharma Treatment of cancers using anti-nkg2a agents
PT3405495T (en) 2016-01-21 2021-05-14 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
KR101926166B1 (en) * 2016-05-24 2018-12-06 재단법인 아산사회복지재단 Method of measuring of nk cell activity using receptor synergy and diagnosing of nk cell activity-mediated desease
US11795222B2 (en) 2018-03-13 2023-10-24 Innate Pharma Treatment of head and neck cancer
CN113874035A (en) * 2019-03-29 2021-12-31 德伦生物公司 Method for reducing levels of large granular lymphocytes and natural killer cells
US20230312753A1 (en) * 2020-05-04 2023-10-05 Immunorizon Ltd. Precursor tri-specific antibody constructs and methods of use thereof
US11795228B2 (en) 2020-09-30 2023-10-24 Dren Bio, Inc. Anti-CD94 antibodies and methods of use thereof
CN114524876A (en) * 2020-11-23 2022-05-24 南京北恒生物科技有限公司 Antibodies targeting NKG2A and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
JPH03112485A (en) 1989-09-22 1991-05-14 Olympus Optical Co Ltd Hla-c gene and dna probe, and transformant cell
JPH03112486A (en) 1989-09-22 1991-05-14 Olympus Optical Co Ltd Hla-b35 gene and dna probe, and transformant cell
JPH03112487A (en) 1989-09-22 1991-05-14 Olympus Optical Co Ltd Hla-bw 53 gene, dna probe and transforming cell
JPH03112484A (en) 1989-09-26 1991-05-14 Nisshin Seito Kk Novel restriction enzyme and its production
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JPH03112484U (en) 1990-03-02 1991-11-18
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
US5489525A (en) 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
KR100261941B1 (en) 1994-07-13 2000-07-15 나가야마 오사무 Reconstituted human antibody against human interleukin-8
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
EP0979102A4 (en) 1997-04-30 2005-11-23 Enzon Inc Polyalkylene oxide-modified single chain polypeptides
GB9725764D0 (en) 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
PL358215A1 (en) 2000-03-24 2004-08-09 Micromet Ag Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
US6999941B1 (en) 2000-07-11 2006-02-14 Amazon.Com, Inc. Providing gift clustering functionality to assist a user in ordering multiple items for a recipient
AU1922902A (en) 2000-12-18 2002-07-01 Inst Nat Sante Rech Med Novel means for the diagnosis and therapy of CTCL
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20030095965A1 (en) 2001-05-02 2003-05-22 Katrien Van Beneden Antibodies to Ly49E and CD94/NKG2 receptors
AU2002325333B2 (en) 2001-07-19 2008-04-03 Innate Pharma NTB-A, a surface molecule involved in natural killer cells activity
CN1555272A (en) 2001-07-31 2004-12-15 �ո��� Compositions and methods for modulation of immune responses
WO2003095965A2 (en) 2002-05-13 2003-11-20 Envirotech Products Limited Tank valve testing method
DK1517921T3 (en) 2002-06-28 2006-10-09 Domantis Ltd Immunoglobulin single variable antigen binding domains and double specific constructs thereof
PT1572744E (en) 2002-12-16 2010-09-07 Genentech Inc Immunoglobulin variants and uses thereof
CN1748143A (en) 2002-12-16 2006-03-15 健泰科生物技术公司 Transgenic mice expressing human cd20 and/or cd16
CN104645327A (en) 2003-07-24 2015-05-27 依奈特制药公司 Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
WO2005040219A1 (en) 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
WO2005105849A1 (en) 2004-04-30 2005-11-10 Innate Pharma Compositions and methods for treating proliferative disorders such as nk-type ldgl
SG155883A1 (en) * 2004-06-03 2009-10-29 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
CA2591059C (en) 2004-12-28 2018-11-06 Innate Pharma Monoclonal antibodies against nkg2a
CN101107269B (en) 2004-12-28 2012-10-31 依奈特制药公司 Monoclonal antibodies against NKG2A
WO2007042573A2 (en) * 2005-10-14 2007-04-19 Innate Pharma Compositions and methods for treating proliferative disorders
CN101484471B (en) 2006-06-30 2013-11-06 诺沃-诺迪斯克有限公司 Anti-NKG2A antibodies and uses thereof
BRPI0908508A2 (en) * 2008-01-24 2016-03-22 Novo Nordisk As humanized anti-human nkg2a monoclonal antibody
CN107693791B (en) 2010-02-26 2022-06-07 诺沃—诺迪斯克有限公司 Compositions comprising stable antibodies
WO2012172102A1 (en) * 2011-06-17 2012-12-20 Novo Nordisk A/S Selective elimination of erosive cells
EP3186282A1 (en) 2014-08-28 2017-07-05 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations
JP2017538660A (en) 2014-09-16 2017-12-28 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Treatment plan using anti-NKG2A antibody
CN113929782B (en) 2014-09-16 2024-06-21 依奈特制药公司 Neutralization of inhibitory pathways in lymphocytes
EP3659625A1 (en) 2014-10-23 2020-06-03 Innate Pharma Treatment of cancers using anti-nkg2a agents
PT3405495T (en) 2016-01-21 2021-05-14 Innate Pharma Neutralization of inhibitory pathways in lymphocytes

Also Published As

Publication number Publication date
BR112013032217A2 (en) 2016-11-22
JP6334395B2 (en) 2018-05-30
AU2012268939B2 (en) 2017-05-04
JP2014519522A (en) 2014-08-14
US9512228B2 (en) 2016-12-06
US20170073417A1 (en) 2017-03-16
MX342131B (en) 2016-09-14
WO2012172102A1 (en) 2012-12-20
BR112013032217B1 (en) 2021-01-19
CA2838220A1 (en) 2012-12-20
US11697687B2 (en) 2023-07-11
RU2617056C2 (en) 2017-04-19
RU2013158625A (en) 2015-07-27
EP2721068A1 (en) 2014-04-23
EP2721068B1 (en) 2018-12-05
US20140161802A1 (en) 2014-06-12
US20200109206A1 (en) 2020-04-09
CN103635487B (en) 2016-10-12
CN103635487A (en) 2014-03-12
KR102047248B1 (en) 2019-11-21
CA2838220C (en) 2020-07-21
KR20140037918A (en) 2014-03-27
MX2013014203A (en) 2014-01-20

Similar Documents

Publication Publication Date Title
US11697687B2 (en) Selective elimination of erosive cells
AU2012268939A1 (en) Selective elimination of erosive cells
CN103596982B (en) Therapeutic antibodies
TWI653242B (en) anti-IL-23 antibody
RU2670743C9 (en) Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AU2012314390B2 (en) Anti-ICAM-1 antibodies to treat multiple-myeloma related disorders
US20230272067A1 (en) Human monoclonal antibodies against tigit for immune related diseases
EP3443981B1 (en) Llt-1 antibodies with new functional properties
US20140065154A1 (en) Tlr3 binding agents
ES2719849T3 (en) Selective removal of erosive cells
RU2782950C2 (en) Subcutaneous injection of anti-cd38 antibodies
JP2017125040A (en) Methods for treating conditions using antibodies that bind colony stimulating factor 1 receptor (csf1r)

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVO NORDISK A/S, DENMARK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SOEDERSTROEM, KALLE;GALSGAARD, ELISABETH DOUGLAS;SIGNING DATES FROM 20140122 TO 20140204;REEL/FRAME:063741/0858

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION